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upon Tyne, United KingdomBackground In 2010, after regulatory review of rosiglitazone licensing, the US Food and Drug Administration (FDA)
requested a reevaluation of cardiovascular end points in the RECORD trial.
Methods Automated screening of the original clinical trial database and manual case report form review were performed
to identify all potential cardiovascular and noncardiovascular deaths, and nonfatal myocardial infarction (MI) and stroke
events. Search techniques were used to find participants lost to follow-up, and sites were queried for additional source
documents. Suspected events underwent blinded adjudication using both original RECORD end point definitions and new FDA
end point definitions, before analysis by the Duke Clinical Research Institute.
Results The reevaluation effort included an additional 328 person-years of follow-up. Automated screening identified 396
suspected deaths, 2,052 suspected MIs, and 468 suspected strokes. Manual review of documents by Duke Clinical Research
Institute clinical events classification (CEC) coordinators identified an additional 31 suspected deaths, 49 suspectedMIs, and 28
suspected strokes. There were 127 CEC queries issued requesting additional information on suspected deaths; 43 were closed
with no site response, 61were closed with a response that no additional data were available, and additional data were received
for 23. Seventy CEC queries were issued requesting additional information for suspected MI and stroke events; 31 were closed
with no site response, 20were closedwith a response that no additional data were available, and 19 resulted in additional data.
Conclusions Comprehensive procedures were used for rigorous event reascertainment and readjudication in a
previously completed open-label, global clinical trial. These procedures used in this unique situation were consistent with other
common approaches in the field, were enhanced to address the FDA concerns about the original RECORD trial results, and
could be considered by clinical trialists designing event readjudication protocols for drug development programs that have
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ORECORD trial was a randomized, open-label trial com-
paring rosiglitazone-containing combination therapy for
type 2 diabetes with the dual oral combination of
metformin and a sulfonylurea. The trial (ClinicalTrials.
gov, NCT00379769) was conducted from 2001 to 2008.2
The results of theRECORD trial, togetherwith other data,
were reviewed and discussed in July 2010 by an Advisory
Committee of the US Food and Drug Administration (FDA).
After the review, the FDA required the sponsor of the
RECORD trial, GlaxoSmithKline (GSK), to commission a
comprehensive, reevaluation of the cause of deaths and of
2 nonfatal events: myocardial infarction (MI) and stroke.
The Duke Clinical Research Institute (DCRI) was selected
to conduct the review. Results of the reevaluation are
presented separately.3 This article reports themethods that
were developed to perform the reevaluation effort. The key
objectives of this effort were to (1) systematically identify
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(2) derive end-of-follow-up dates; (3) adjudicate all
suspected events by original RECORD definitions and by
contemporary definitions under development by the FDA
(Standardized Data Collection for Cardiovascular Trials
Initiative); and (4) report event rates and time-to-event
analyses by treatment group.
Methods
Planning
The DCRI coordinated all clinical events classification (CEC)
operations for the RECORD reevaluation protocol in collabora-
tion with the sponsor. In the planning phase, leadership from
the sponsor, the FDA, and the DCRI discussed critical issues to
design the reevaluation effort, particularly the event identifica-
tion (“triggering”) strategy, the need for collection of additional
source documents, and additional ascertainment of lost-to-
follow-up patients. The original RECORD principal investigator
and trial CEC chairman reviewed and commented on the draft
protocol for the reevaluation effort.
The DCRI CEC team created and maintained the CEC charter for
RECORD reevaluation, as well as the adjudication pages used to
capture key data required for the efficient and accurate adjudica-
tion and final analysis of end point events. The DCRI CEC charter
(online Appendix A) describes the operations followed for
identification of suspected events, collection of data and source
documents, DCRI reevaluation, and quality control. It also details
the organization, roles, and activities of the DCRI CEC group,
including the physicians who formed the DCRI CEC Committee.
The DCRI CEC group systematically identified, adjudicated,
and classified the following suspected events using prespecified
criteria: cause of death, MI, and stroke.
Duke Clinical Research Institute CEC Committee
members
The DCRI CEC Committee members were physicians who
provided clinical expertise in development of the CEC processes
and CEC adjudication forms and participated in adjudication of
suspected end points. No sponsor representatives or members
of the original RECORD CEC committee served on the DCRI CEC
Committee. Members included faculty-level endocrinologists,
cardiologists, neurologists, and other physicians with relevant
clinical expertise, involvement in clinical research, and prior
CEC experience.
All CEC Committee physicians were trained regarding the
RECORD reevaluation protocol and event definitions before
starting event adjudication. Documented training comprised an
overview of the protocol, trial timelines, specific definitions and
supporting documentation for each event type, adjudication
form instructions, and adjudication timeline expectations.
Identification of suspected events
A comprehensive process to “trigger” all potential death, MI,
and stroke events included both automated and manual trigger
procedures (Figure 1). This process was designed to systemat-
ically identify events from investigator-identified events, case
report forms (CRFs), and adverse event (AE), and serious AE
(SAE) reporting; to try to mitigate any potential reporting bias(RECORDwas open label); and to ensure that all potential events
were identified and reviewed. Vital status in those participants
lost to follow-up was ascertained, as detailed below.
Automated trigger procedures. The automated pro-
cedures included a computer program (trigger program) that
was applied to the original RECORD CRF clinical database,
looking for evidence that an event may have occurred. The
following CRFs and CRF subforms were screened by the
automated trigger program: Adverse Event Form, Serious
Adverse Event Form, Death Form, Study Continuation/With-
drawal Form, Tracking Form for Completely Withdrawn
Patients, Survival Status Form, Third Party Survival Data Form,
and Cardiovascular Procedure/Amputation End Point Form. All
Medical Dictionary for Regulatory Activities–coded AE and SAE
terms in the clinical database were electronically screened to
identify potential cardiovascular end points. Determination of
which terms would be used to identify cardiovascular end points
was made by DCRI clinical and safety experts. Details of the
automated procedures and trigger specifications are contained
within the RECORD reevaluation CEC trigger specifications
(online Appendix B). Each potential event was tracked
throughout the process using a unique identifier.
Manual trigger procedures. The DCRI CEC coordina-
tors manually reviewed all paper documents separately from the
output from the automated trigger program. These coordinators
had extensive experience in cardiology event reporting and in
CEC methodologies. A quality control process was implemented
for the manual review (see below).
Source documents and further data collection.
Participant identifiers, treatment assignment, and other glucose-
lowering agent use were redacted from all data sent to the DCRI
CEC, a task performed a priori by GSK. Blinding was checked by
DCRI CEC coordinators and assistants before event dossiers
were sent to CEC physicians, further redaction being performed
if necessary.
The DCRI also accessed the source documents used by the
original RECORD CEC (Table I). For newly identified events,
source documents required are listed in Table II. Source
documents were requested from investigator sites for both
previously adjudicated and new end points, including the
former missing documents. When needed by the DCRI CEC,
additional information was requested (up to 2 attempts) from
sites and locally redacted before submission to the CEC. All new
data were identified as such to allow evaluation both with the
original and the original plus new data, and thus, after
completion of readjudication and database lock, comparisons
between original and new adjudication of events. Documents
not in English were translated by an outside vendor.
Ascertainment of vital status. Using theRECORDstudy
data supplied by GSK, DCRI identified patients whose vital status at
the end of the study was not known or documented. MediciGlobal
(King of Prussia, PA), was contracted to search globally for vital
status information for these patients. Data were updated for newly
discovered deaths, known deaths with new information, and new
“last-known-alive” dates.
Database transfers and conversion for end
points reevaluation
Electronic data containing the raw CRF data were transferred
as SAS data sets in prespecified format from GSK to the DCRI in 3
Figure 1
MI/Stroke Trigger Process Flow
MI/Stroke
Endpoint Form
completed
MI/Stroke trigger
with SAE form and
SAE narrative/
summary completed
MI/Stroke
trigger with AE
Form only (no
hospitalization
or SAE)
MI/Stroke trigger
with
Hospitalization
Endpoint Form
completed
No
One Coordinator or MD
reviews data present.
(10% of Coordinator
reviewed triggers will
be re-reviewed by MD
for QC)
Data indicate a potential MI or
Stroke event?
Yes
Adjudication
form
completed
Site queried for
documents
Documents received?
MD determines
additional documents
are required?
MI Triggers: Phase I Review Complete
Stroke Triggers: Neurologist/Phase II Review Complete
Comment entered on
Adjudication form
indicating required
documents
MI Triggers: Phase I Review by 2 independent MDs
Stroke Triggers: Neurologist/Phase II Review
Yes No
Yes
No
No event
Trigger process. MD, CEC committee physician; QC, quality control.
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to provide electronic identification of events for referral to the
DCRI CEC. DCRI programmers checked and, where necessary,
requested further redaction and data retransfer. Phase 2 transfer
occurred after completion of DCRI electronic identification ofpotential events; this transfer included treatment start and stop
dates (blinded) and a data set containing the identification
numbers for deaths, as originally reported. Phase 3 transfer
included treatment information (unblinded); these data were
kept firewalled from the clinical team until all DCRI
Table I. Original RECORD CEC source documents
Event Document
Death (in hospital) Death summary or
investigator narrative
Autopsy report
Death (out of hospital) Investigator narrative
Autopsy report
Police report/family records/
available documentation
describing circumstances of death
Hospitalization for acute MI Discharge summary or investigator
narrative with ECG description
and cardiac biomarker results
ECG (if not in discharge summary)
Cardiac biomarker results
(if not in discharge summary)
Hospitalization for stroke Discharge summary or investigator
narrative with neurologist investigations
neurologic report
(if not in discharge summary)
Abbreviation: ECG, Electrocardiogram.
Table II. RECORD CEC reevaluation source documents for new
events
Event Document
Death Death summary
Investigator summary
Autopsy report
MI Discharge summary
Baseline and 2 event ECGs
Cardiac biomarker results
Stroke Discharge summary or investigator narrative
Imaging reports (CT/CTA, MRI/MRA)
Neurology consult notes
Abbreviations: ECG, Electrocardiogram; CT, computed tomography; CTA, computed
tomography angiography; MRI, magnetic resonance imaging; MRA, magnetic
resonance angiography.
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folder on the DCRI server, and access was granted only to the
unblinded statistical team members responsible for producing
the report of readjudicated events.
Event adjudication
TheDCRICECprocess is summarized in Figure 2. TheDCRICEC
physicians adjudicated each suspected event identified by the
automated or manual trigger procedures described above using
prespecified end point criteria based on the preponderance of the
evidence, clinical knowledge, and experience. All events were
reviewed using the original RECORD end point definitions
themselves, reflecting European Society of Cardiology recommen-
dations, and—by request of the FDA—were also reviewed using
new FDA end point definitions that resulted from the Standardized
Data Collection for Cardiovascular Trials Initiative.4,5 Online
Appendix C displays the original RECORD end point definitions,
and online AppendixD provides the new FDA definitions. The key
differences between the original RECORD end point definitions
and the new FDA definitions are shown in Table III.
Potential events triggered from an AE term only, with no
hospitalization or source documentation present, were
reviewed by a single clinician (DCRI CEC coordinator or
physician) to confirm whether there was a potential event. If
that was the case, the event dossier and data were forwarded for
review by physicians, including possible stroke events by a
neurologist. Events were allocated to 2 physicians acting
independently, and for MI, a separate pair of physicians were
used for original and FDA definitions. If one reviewer requested
and received additional information, it was also given to the
other reviewer.
Where the 2 reviewers agreed in adjudication of the
suspected event, the end point classification was deemed
complete. Otherwise, the event was referred to an adjudication
committee. At least 3 faculty physicians were required for this,
with a decision made by consensus. The basis of the decision
was documented. If further information was requested, the
event was reviewed at a further meeting.For suspected strokes, phase 1 review required 2 neurologists or,
alternatively, review by the CEC committee, which then had to
include a neurologist (Figure 2).
Quality control of the evaluation process
A random sample of adjudicated events was re-reviewed by a
committee of at least 3 DCRI CEC faculty physicians who were
blind to the initial decision. The quality control plan was based
on a 5% random sample of adjudicated events (but greater than
the square root of the number of events plus 1) generated by the
DCRI CEC statistician. The sample was weighted toward the
earlier part of the adjudication process for mortality events.
A “major” discrepancy was declared when there was
disagreement on whether a defined event had occurred. A
“minor” discrepancy involved disagreement on the date, time,
type, or evidence. Major discrepancies were allowed to update
the adjudication database but only after further committee
review and discussion with the CEC principal investigator.
Events with a minor discrepancy were not re-reviewed, and the
results remained unchanged in the database.
Quality control of the manual trigger program
A random sample of the documents that were screened
during the manual trigger procedures were rescreened by a
physician using the same documents originally screened by the
coordinators. The sample size was 5% of the participants
screened and not triggered for an end point event, plus 5% of all
other manual triggers.
Statistical analysis
Details of the statistical analysis plan (SAP) are described in
the online Appendices E and F. In brief, the first phase of the
event reevaluation process entailed adjudication of all-cause and
cardiovascular (or unknown cause) mortality, and comparative
analyses were completed. In the second phase, MIs and strokes
were adjudicated, and analyses of these and major adverse
cardiac events (earliest of MI, stroke, or cardiovascular death)
were conducted. All analyses were performed for both original
RECORD CEC and new FDA definitions.
For each end point, the hazard ratio (HR; rosiglitazone
compared with metformin/sulfonylurea) and 95% confidence
intervals were calculated using Cox proportional hazard
Figure 2
Clinical events classification process flow. MD, CEC Committee physician; QC, quality control.
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sulfonylurea). The HRs (95% CIs) were also calculated for each
background therapy group, and a test for interaction was
conducted at the P b .10 level. This statistical approach was
similar to that used in the original RECORD study. Event rates
(per 100 years) were reported for each end point.Mortality and major adverse cardiac events
A DCRI statistician (G.H.) participated in the development of
the event trigger rules, adjudication forms, and query rules;
drafted the SAP; created the analysis data set; wrote the
reporting specifications; and oversaw the statistical program-ming and quality control. She remained blinded to treatment
allocation throughout phases 1 and 2 (see above). A DCRI
faculty/reviewing statistician (R.B.) who provided consultation
on these statistical activities also remained so blinded. These
personnel controlled all access to treatment assignments or use
of other glucose-lowering medications.
Two DCRI statisticians were also unblinded to review the
mortality event reevaluation results once completed.Blinding
Formal procedures were identified to ensure blinding of the
randomly assigned treatment group until knowledge of the
Table III. Key differences between original RECORD and new FDA end point definitions
Event Original RECORD end point definitions New FDA end point definitions
Death CV death will include death after heart failure, death after acute MI,
sudden death, and death due to acute vascular events.
CV death includes death resulting from an acute MI, sudden cardiac
death, death due to heart failure, death due to stroke, and death
due to other CV causes.Death due to acute vascular events is defined as death due to aortic
dissection, aortic aneurysm, pulmonary embolism, stroke, or any
other vascular cause.
Death due to other CV causes refers to a CV death not included in
above categories (eg, dysrhythmia, pulmonary embolism, CV
intervention, aortic aneurysm rupture, or peripheral arterial disease).Deaths with an unknown cause will be counted as CV death for the
primary end point analysis. Mortal complications from cardiac surgery or nonsurgical
revascularization will be classified as CV death.
MI Hospitalization plus troponin I or T N ULN or CK/CK-MB ≥ 2 × ULN,
plus one of the following:
Spontaneous MI: cardiac biomarkers N ULN, plus ischemia presentation
or ECG evidence of ischemia or new pathological Q waves or imaging
evidence of new loss of viable myocardium or new regional wall motion
abnormality or autopsy evidence of acute MI
Peri-PCI MI: troponin or CK-MB N 3 × ULN within 48 h post-PCI or new Q
waves post-PCI or autopsy evidence of MI post-PCI
• Typical symptoms of ischemia
Peri-CABG MI: troponin or CK-MB N 5 × ULN, plus new Q waves or new
LBBB or angio evidence of new graft or native artery occlusion or
operating room complication resulting in loss of myocardium or imaging
evidence of new loss of viable myocardium
Peri-CABG MI: autopsy evidence of acute MI post-CABG
• New pathological ECG findings as defined in 20005
Silent MI: no evidence of acute MI, plus new Q waves or imaging
evidence of a region of loss of viable myocardium that is thinned and fails
to contract or autopsy evidence of a healed or healing MI
Stroke Hospitalization plus Acute episode of neurologic dysfunction caused by focal or global brain,
spinal cord, or retinal vascular injuryRapidly developed clinical signs of focal or global disturbance of
cerebral function lasting more than 24 h (unless interrupted by
thrombolysis, surgery, or death), with no apparent cause other than
a vascular origin
Ischemic: acute episode of focal cerebral, spinal, or retinal dysfunction
caused by an infarction of the central nervous system tissue
Strokes resulting from blood diseases, brain tumors, brain
metastasis, or trauma should be excluded.
Hemorrhagic: acute episode of focal or global cerebral or spinal
dysfunction caused by a nontraumatic intraparenchymal, intraventricular,
or subarachnoid hemorrhage
Abbreviations: CV, Cardiovascular; ULN, upper limit of normal; CK, creatine kinase; ECG, electrocardiogram; PCI, percutaneous coronary intervention; CABG, coronary artery
bypass graft; LBBB, left bundle-branch block.
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was completed. The principal investigator for the reevalua-
tion (K.W.M.) remained blinded until statistical analyses
were complete.
The DCRI faculty lead for the first phase reevaluation of
mortality (L.K.N.) was unblinded to review these reevaluation
results once complete. The mortality report was reviewed by 9
GSK personnel who were firewalled from the reevaluation
process to check the accuracy of text citing the original
RECORD trial or describing steps taken by GSK to obtain
additional follow-up information. This group was also respon-
sible for fulfilling the study sponsor's regulatory submission
requirements and informed the GSK Corporate Executive
Team about the completion of the first phase and apprised
them of the results.
The DCRI faculty lead for the second phase reevaluation of
major adverse cardiac events (R.D.L.) was unblinded after the
database lock to review the results of reevaluation of major
adverse cardiac events, MI, and stroke and to help prepare the
study report of the second phase.
Role of the funding source
The role of the sponsor (GSK, King of Prussia, PA) in the
conduct of the study has been published previously.2 Funding
for the reascertainment and reevaluation was provided to DCRI.
The sponsor and members of the RECORD Steering Committeereviewed and commented on the protocol and procedures of
reevaluation before any reascertainment activity but did not
have any further role until reevaluation was finalized. It was
planned that the original RECORD leadership and DCRI
leadership would review the results of the reevaluation effort
and review discrepant adjudications as a learning activity. Both
DCRI and the RECORD Steering Committee representatives
made the decision to publish the findings and have written the
manuscript jointly. The manuscript was reviewed by sponsor
representatives for accuracy.Results
Myocardial infarction/stroke event triggers
A total of 2,597 MI/stroke triggers were identified,
2,101 MIs and 496 strokes. The automatic trigger
program identified 2,052 MIs and 468 strokes, and
manual document review identified 49 MIs and 28
strokes. Of the 2,597 events triggered, there were 4 for
which there was no evidence in the medical records that
an event occurred, whereas 697 duplicate triggers for
another event were set to linked status. (ie, if more than 1
trigger fired for the same event, only 1 trigger was
adjudicated, and the other triggers were listed at the
bottom of the CEC adjudication forms as “supplemental
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unique events; these 1,896 MI/stroke event triggers
were then identified for adjudication. Thus, there were
no duplicate events, but just duplicated triggers for other
events, which were evaluated and resolved by the DCRI
group before adjudication.
Myocardial infarction/stroke queries
For the suspected MI and stroke events, 70 CEC queries
requesting additional information from the site investiga-
tors or coordinators were issued with the following
results: 31 queries were closed with no response from the
site, 20 queries were closed with a response that no
additional data were available, and 19 queries were
closed with additional data being received. Of these 19, 2
resulted in changed MI adjudication results (yes/no), one
in each direction.
Death event triggers
A total of 427 death event triggers were identified. The
automatic trigger program identified 396 deaths, and 31
deaths were identified manually. Of the total, 100 triggers
were not adjudicated because there was no evidence on
checking the medical record that a death had occurred.
Death queries
A total of 127 CEC queries were issued for additional
information to follow up on death events classified as
“unknown” and “insufficient information.” The queries
for these 127 patients resulted in 43 with no response
from the site, 61 with a response that no additional data
were available, and 23 closed with additional data
received from the site. Of these 23 queries, 16 deaths
were re-reviewed with no change to the adjudication
result, and 7 events were re-reviewed with a change to
the adjudication result from unknown to a known cause
of death.
Quality control findings
A medical review of 100 randomly selected stroke and
MI events was performed blind to treatment assignment
and original DCRI CEC adjudication outcome. In 93
events, there was no discrepancy in the determination.
There was 1 major discrepancy (change of event
classification), 2 discrepancies involving Q-wave classifi-
cation, and 4 other discrepancies involving event date/
time. A medical review of 25 randomly selected death
events were also performed as part of the quality control
process. There were 2 major discrepancies on cause of
death. Both of them occurred in the first 10 quality
control death cases and were originally called sudden
cardiac deaths; after the quality control review, they were
changed to unknown cause in the database. There were
no major discrepancies in the subsequent 15 quality
control death cases.Discussion
Diabetes is an epidemic disease that is expected to
affect around 450 million people by 2030, with a
substantial increase in incidence in developing coun-
tries.6-8 The direct health care costs of diabetes range
from 2.5% to 15% of annual health care budgets.9
Although intensive glucose control has been associated
with lower rates of MI, it also has been associated with
higher mortality rates, including cardiovascular mortali-
ty.10,11 Conventional therapies for diabetes have not been
tested for cardiovascular outcomes in long-term clinical
trials. In this context, the RECORD study, planned in 2000
and begun in 2001, and later consistent with the FDA's
December 2008 recommendation for study of new
treatments for type 2 diabetes,2 evaluated the cardiovas-
cular safety of rosiglitazone.
The available data on risk of myocardial ischemia among
patients using rosiglitazone are inconclusive. A meta-
analysis of 42 short-term clinical studies (most of which
compared rosiglitazone with placebo), including 14,237
patients with a mean duration follow-up of 6 months,
suggested an association between rosiglitazone use and an
increased risk of myocardial ischemic events.12 Other
studies, including the RECORD trial, comparing rosiglita-
zone with other oral diabetes medications or placebo
(total patients around 14,000, with a mean follow-up of 41
months) have not shown the same risk.2,13,14
Several examples of treatment that improve surrogate
end points, such as decreasing glycated hemoglobin in
patients with diabetes or increasing hemoglobin value in
patients with cancer or renal disease, have subsequently
been found to cause an increase in important clinical
events, including mortality.5,15-19 Indeed, the RECORD
trial confirmed the increased rate of distal fractures in
women identified by ADOPT in 200820 and quantified the
rate of increase of hospitalizations for heart failure.
However, the primary end point was cardiovascular safety
of rosiglitazone, defined as all cardiovascular hospitaliza-
tions. Participants were followed up for 5.5 years, on
average, in a comparative (vs metformin or sulfonylurea)
design. There were several secondary end points includ-
ing a major cardiovascular event composite (cardiovascu-
lar death, MI, or stroke). All cardiovascular end points
were determined by a team of cardiologists/stroke
physician/diabetologists blinded to treatment assignment.
The study reported no difference in the occurrence of the
primary end point in the rosiglitazone group compared
with combined use of metformin and a sulfonylurea.2
The RECORD trial was designed as an open-label study
in which the clinical events were adjudicated in a blinded
fashion. Despite that, concernswere raised by some about
ascertainment bias of clinical events in the study, aswell as
improper processing of some end points, and absence of
systematic identification of potential cardiovascular clin-
ical events remote from the investigator site.21
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undertaken to attempt to address the regulatory,
research, and clinical communities' concerns about the
efficacy and safety of rosiglitazone in people with type 2
diabetes. This effort, which had the collaboration of the
original RECORD trial leadership, sponsor (GSK), the
FDA, and the DCRI, included an intense, and compre-
hensive process to identify all possible events that might
have occurred in the original RECORD trial. The DCRI
CEC group used predefined criteria to review all
suspected incidences of deaths (cardiovascular and
noncardiovascular), MI, or stroke and to judge whether
a death, MI, or stroke had actually occurred. For patients
deemed to have died or had an MI or stroke, the CEC
identified the date of the event. The end of follow-up for
patients who did not experience cardiovascular death,
MI, or stroke was considered to be the last date at which
vital signs were recorded on the CRF.
Clinical events classification efforts are becoming more
common as a result of interactions between the FDA and
pharmaceutical companies. For the RECORD reevaluation,
extensive efforts were made to obtain additional source
documentation for selected events as well as vital status for
patients who did not complete the study follow-up. These
efforts were challenged by multiple factors including
closure of some research sites, lack of current institutional
review board approval, national regulations preventing
additional follow-up, unavailability of principal investigators
and coordinators, and the long elapsed time since the initial
trial had completed. Thus, many queries that were sent to
the sites could not be answered, nor could new
information be obtained from the sites to allow for the
addition of new events to the analysis. It is uncertain
whether additional source document collection would
have resulted in additional events being identified. Re-
searchers may consider this information when planning
retrospective efforts to collect additional clinical data in
previously completed trials or drug development programs.
The analysis of the primary end point using both the
original RECORD end point definitions and the new draft
FDA end point definitions may add relevant information
to rosiglitazone's profile, allow interpretation of the
RECORD trial with a contemporary set of clinical end
point definitions, and provide insights about the value of
the revised definitions compared with historical stan-
dards. There is consensus about the need for standardized
definitions to allow comparison of event rates across trials
and over time, but the specific criteria in the definitions
are often still debated.Conclusions
A comprehensive, systematic, and blinded, program was
designed to reevaluate event ascertainment and adjudication
in the RECORD trial at the request of the FDA. Procedures
included rigorous blinding of randomized treatment assign-ment, collection of additional information about patients
previously lost to follow-up, and systematic identification of
all deaths and suspected MI and stroke events using the raw
data set. Theseprocedures used in this unique situationwere
consistentwith other commonapproaches in the field,were
enhanced to address the FDA concerns about the original
RECORD trial results, and could be considered by clinical
trialists designing event readjudication protocols for drug
development programs that have been completed.
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Charter
Readjudication Protocol AVD115170 “RECORD”
Rosiglitazone Evaluated for Cardiac Outcomes and
Regulation of glycaemia in Diabetes
CEC Charter Effective Date: November 21, 2011
AbbreviationsAbbreviation Definition
CABG Coronary artery bypass graft
CDISC Clinical Data Interchange Standards Consortium
CEC Clinical events classification
CRF Case report form
CT Computed tomography (imaging)
CV Cardiovascular
DCRI Duke Clinical Research Institute
DM Data management
ECG Electrocardiogram
eCRF Electronic case report form
EDC Electronic data capture
FDA Food and Drug Administration (United States)
GSK GlaxoSmithKline
IRB Institutional review board
MACE Major adverse cardiac end points
MedDRA Medical Dictionary for Regulatory Activities
MI Myocardial infarction
MR Magnetic resonance (imaging)
PCI Percutaneous coronary intervention
RECORD Rosiglitazone Evaluated for Cardiac Outcomes and
Regulation of glycaemia in Diabetes
RSG Rosiglitazone
SAE Serious adverse event
SAP Statistical analysis plan1.0. Introduction
The Rosiglitazone Evaluated for Cardiac Outcomes and
Regulation of glycaemia in Diabetes (RECORD) study was
an open-label, randomized trial comparing rosiglitazone-
containing combination therapy for type 2 diabetes with
the most commonly used dual oral combination of
metformin and a sulfonylurea. The study was conducted
between 2001 and 2008 andpublished in 2009. The results
of the RECORD study, together with other data, were
reviewed and discussed at a July 13-14, 2010, jointmeeting
of the Endocrinologic and Metabolic Drugs Advisory
Committee and the Drug Safety and Risk Management
Advisory Committee. After this review, the Food and Drug
Administration (FDA) required the sponsor of the
RECORD study, GlaxoSmithKline (GSK), to commission
a comprehensive independent readjudication, at the
patient record level; to determine the cause of all deaths;
and to adjudicate all suspected nonfatal myocardial
infarction (MI) and all suspected nonfatal stroke end
points of the study.
Representatives from the FDA and GSK have previous-
ly agreed that the readjudication effort will have 2
TIA Transient ischemic attackphases. The first phase will include the readjudication of
all deaths, and those results will be analyzed and
submitted to the FDA. The second phase will include
the readjudication of the nonfatal MI and stroke events.
The second phase will begin before completion of the
first phase.
The Duke Clinical Research Institute (DCRI) has been
asked by GSK to conduct the independent review and
submit results to the FDA for comparison with those
based on the adjudication outcomes from the original
RECORD Clinical Endpoints Committee.
The primary objective of the readjudication is to address
some of the critical FDA concerns about the RECORD trial
that have been detailed. (FDA briefing document: http://
www.fda.gov/downloads/AdvisoryCommittees/
CommitteesMeetingMaterials/Drugs/Endocrinologicand
MetabolicDrugsAdvisoryCommittee/UCM218493.pdf).22
Key specific objectives include the following:
• Systematic identification of all deaths, all suspected
MIs, and all suspected stroke events using all
available data sources by reviewers who are blinded
to patient treatment assignment
• Standard preparation of all events for adjudication
without filtering of suspected events by persons
who have knowledge (or potential knowledge) of
patient treatment assignment
• Adjudication of all events using the original RECORD
end point definitions and contemporary definitions
under development by FDA through the Standardized
Data Collection for Cardiovascular Trials Initiative
2.0. Role of the DCRI RECORD CEC group
The DCRI RECORD CEC group is responsible for the
conduct of the CEC operations for the RECORD Read-
judication Protocol, in collaboration with the sponsor,
GSK. The DCRI CEC group creates and maintains the
CEC Charter and will develop the event adjudication
pages to capture key data required for the efficient and
accurate adjudication and final analysis of the following
suspected events:
• Cause of Death
• MI
• Stroke
3.0. RECORD CEC group organization
The RECORD CEC group will systematically identify,
adjudicate, and classify suspected events while blinded to
treatment assignment as well as all glucose-lowering
agents. All subject personal identifiers, treatment assign-
ment, and glucose-lowering agents will be redacted from
the subject data, including all source documents.
RECORD subject study numbers will not be redacted.
The RECORD CEC group will develop trial-specific
processes for the identification of suspected end point
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and the adjudication of the suspected end point events
using prespecified criteria.
3.1. Qualifications of the RECORD CEC Commit-
tee members. The RECORD CEC Committee members
will consist of physicians who will provide clinical
expertise in the development of the CEC processes and
CEC adjudication and reporting forms, as well as in the
adjudication of suspected end points. No GSK represen-
tatives will serve on the RECORD CEC Committee.
Members may include endocrinologists, cardiologists,
neurologists, or other physicians who have relevant
clinical expertise and prior CEC experience.
Documentation of the required qualifications for the
selected RECORDCECphysicianswill bemaintained at the
DCRI in the form of current curricula vitae. Membership in
the RECORD CEC Committee is for the duration of the
study unless the member is deemed by the RECORD CEC
chairperson in conjunction with the principal investigator
to be unable to fulfill his/her responsibilities.
All RECORD CEC physicians will undergo training
regarding the RECORD study before starting event
adjudication. Training will be conducted by the RECORD
CEC chairperson and/or RECORD CEC coordinators.
Training material is produced and provided to the CEC
physicians. This consists of an overview of the protocol,
trial timelines, a detailed list and definition of each event
to be adjudicated, supporting source documentation for
each event, adjudication form completion instructions,
and adjudication timeline expectations. Training docu-
mentation for each reviewer is maintained by the CEC.
3.2. DCRI RECORD CEC chairperson/director.One
DCRI faculty member will be appointed as the RECORD
CEC chairperson. The specific responsibilities of the CEC
chairperson include the following:
• Preside over RECORD CEC readjudication confer-
ence calls and meetings or delegate to an appropri-
ate designee from the CEC
• Ensure that ongoing QC reviews of readjudicated
events are conducted and that the readjudication
process is being conducted according to the
RECORD CEC readjudication Charter and that end
point criteria are being accurately applied
• Participate in the readjudication process
• Provide clinical support to the RECORD CEC
coordinators and physicians
3.3. RECORD CEC physicians. The RECORD CEC
physicians are responsible for the following:
• Adjudicate and classify events, with accurate and
consistent application of the event criteria
• Participate in discussions related to event criteria
and the application of the criteria
• Participate in adjudication conference calls and
meetings• Communicate schedule conflicts, including extend-
ed time away from office, to the RECORD CEC
coordinator and chairperson
• Adherence to the event adjudication timeline
3.4. DCRI RECORD CEC operations director. The
specific responsibilities of the RECORD CEC operations
director include the following:
• Participate as needed in project conference calls and
meetings
• Serve as a resource for the RECORD CEC coordinator
• Facilitate weekly project reviews with the RECORD
CEC coordinator
• Provide ongoing support and feedback to the
operations team
3.5. DCRI RECORD CEC project leader. The
RECORD CEC project leader is responsible for the
following:
• Develop the RECORD CEC project plan (in concert
with team members) to include timelines, processes
for clinical research studies, and milestones and
recommend amendments to the RECORD CEC
Charter as appropriate
• Develop and implement training and new processes
in CEC to ensure that work flow is consistent with
CEC SOPs
• Develops performance and process improvement
strategies when appropriate
3.6. DCRI RECORD CEC coordinators. The RE-
CORD CEC coordinators are responsible for the overall
conduct of the CEC activities. Specific responsibilities
include but are not limited to the following:
• Create and maintain the RECORD CEC Charter
• Develop efficient systems and work instructions for
the RECORD CEC team
• Train and oversee the activities associated with
adjudicationwork of the RECORDCEC teammembers
• Organize and facilitate the RECORD CEC Committee
meetings
• Manage the workflow and ensure timelines are met
• Review all end point–specific source documents
and CRF data to ensure that all available data have
been supplied to the CEC physicians
• Review and process potential events triggered from
AE term only
• Issue queries to the sites for additional source
documents as necessary
• Work with RECORD Principal Investigator and
RECORD CEC chairperson to develop electronic
and manual trigger specifications to identify all
potential events
• Ensure that all events identified from trigger
specifications have been reviewed as appropriate
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Section 4.1.2) to ensure that all potential events are
identified
• Work with RECORD Principal Investigator and
RECORD CEC chairperson to develop adjudication
forms
3.7. RECORD CEC clinical data assistant. Specific
responsibilities include, but are not limited to, the
following:
• Prepare and track event packets
• Data enter RECORD adjudication forms into RE-
CORD CEC database (InForm)
• Generate reports
• Assist the CEC coordinator in the logistics and
conduct of the CEC Committee adjudication
meetings
3.8. RECORD CEC clinical trial assistant. Specific
responsibilities include, but are not limited to, the
following:
• Track source documents into the incoming docu-
ment center
• Track subject folders into the CEC Tracking
Database
• Assist CEC clinical data assistant to prepare and track
event packets as necessary
• Assist the RECORD CEC coordinator in the collec-
tion of source documents
4.0. Operations
4.1. Identification of suspected events. A compre-
hensive process to identify or “trigger” all suspected end
point events will be developed. Automated and manual
procedures will be implemented. This process is
designed to systematically identify the events from all
data sources in which events may have been reported by
the site investigators. This approach will be used to
mitigate any potential reporting bias and to ensure that all
potential events are identified and reviewed.
4.1.1. Automated trigger program. The automated procedures
will include a computer program (trigger program) that
includes, but is not limited to, the following:
• Screening of all Adverse Experience (AE) and
Serious Adverse Experience (SAE) forms from the
CRF data fields in the GSK RECORD data sets.
• Prespecified Medical Dictionary for Regulatory
Activities coded terms will be used. The coded
preferred terms were reviewed by clinical, CEC, and
safety experts to identify terms that would poten-
tially be indicative of an end point with a low
threshold. A similar approach has been used in
previous readjudication efforts.
• Death Form (Form D) when present in the database.
Initial trigger specifications will be defined at the
start of the program; however, they may bemodified during the course of the readjudication
process, as needed. Any modifications will be
documented and a rationale provided. The trigger
specifications will be detailed in a separate docu-
ment, titled RECORD Readjudication Trigger
Specifications.
4.1.2. Manual trigger procedures. The RECORD CEC coordina-
tors will perform a manual review of paper documents as
well as reviewing the output from the automated trigger
program. The CEC coordinators reviewing the paper
documents have extensive experience in cardiology
event reporting and CEC methodologies. A quality
control (QC) process will be implemented for the manual
review. Paper sources that the CEC coordinators will
review to identify potential end points include, but are
not limited to, the following:
• The unscheduled visit form (all visits) that inquires
about hospitalizations (Hospitalization or Accident and
Emergency Department Visit End Point Form) will be
used to screen for potential end points. Cardiovascular
and noncardiovascular reasons for admission will be
assessed for review for potential MI and stroke end
points. The following is a list of reasons that have been
used in prior programs: heart failure, MI, acute
coronary syndrome, unstable angina/cardiac chest
pain, atrial fibrillation/flutter, other supraventricular,
tachyarrhythmia, ventricular dysrhythmia, acute renal
failure, acute or chronic renal failure, renal disease,
other renal, stroke, transient ischemic attack, hyper-
tension, hypotension, syncope/pre/syncope, periph-
eral arterial embolus, deep venous thrombosis,
pulmonary embolus, vascular procedure, chronic
obstructive pulmonary disease, and pneumonia.
• Source documents used as part of the original
RECORD CEC adjudication process and any additional
source documents collected as part of the read-
judication activities (discharge summaries, progress
notes, pertinent lab values, and physician narratives)
• Investigator verbatim terms
• All SAE and AE forms
• All cases that were sent to the original RECORD
CEC; this would include end points that were
adjudicated as non-end points and all cases that were
later deleted by the investigator
• All Death End Point Forms
• All MI/Unstable Angina End Point Forms
• All Stroke/TIA End Point Forms
• All hospitalizations
• All Survival Status Forms
• All Documentation of Third Party Survival Data Forms
• All Tracking Forms for CompletelyWithdrawn Patients
• All Study Completion Forms
• All available12-lead electrocardiogram (ECG) trac-
ings for subjects who were not included in the
RECORD ECG substudy
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were included in the RECORD ECG substudy and
triggered for a potential MI event per automated
trigger program
• All available 12-lead ECG tracings for subjects who
were included in the RECORD ECG substudy and
were determined to have a new Q-wave MI per
substudy analysis
Both SAEs and AEs that were deleted by RECORD
investigators will be identified from the audit trail of the
study's electronic data sets, which GSK provided to DCRI.
The electronic data sets will be sent to the DCRI before
the event packet files, which include data from the CRF
and source documents.
Each CEC trigger will have a unique identifier assigned
to it to track each event through the CEC process.
Specific Manual Trigger Procedures will be documen-
ted in a separate document, titled RECORD Readjudica-
tion Trigger Specifications.
4.2. Collection of data. All data sent to the DCRI
RECORD CEC group will have subject personal identi-
fiers, treatment assignment, and glucose-lowering agents
redacted. This will include electronic data sets as well as
source documents and paper CRFs. GlaxoSmithKline is
responsible for the redacting before delivery of data or
documents to the DCRI. The RECORD CEC coordina-
tors, clinical data assistant, and clinical trial assistants
will ensure that information has been blinded or
redacted done before sending event packets to the
CEC physicians. If, during the course of DCRI activities,
it is noted that information that should have been
redacted was not, then the DCRI RECORD CEC
coordinators, clinical data assistant, and/or clinical trial
assistants will redact the information, document the
event, and notify GSK. Event packets that will include
the contents that were used in the original adjudication
process will be provided to the CEC.
When additional information is needed to aid in the
CEC adjudication, sites will be contacted directly by DCRI
CEC for supporting documentation or data clarification to
help render an adjudicated result. Duke Clinical Research
Institute CEC will generate a request for source docu-
ments for end points that were previously adjudicated as
well as for all new end points. Duke Clinical Research
Institute CEC will also request any documents from sites
that were missing from the previous adjudication
process. Requests sent by the DCRI CEC coordinator
will also be directly entered in the CEC tracking database.
Sites will submit the additional information directly to the
DCRI CEC RECORD e-mail inbox. The DCRI CEC
coordinator will note that information was obtained
using the CEC tracking form. Additional documentation
that is added to event packet will be noted as “new
information” at the top of the page of the source
document and tracked in the CEC tracker so thatcomparisons between the readjudication results and the
original adjudication results will allow analysis of whether
additional source documents were used during the
readjudication process.
When additional source documentation is needed to
support the adjudication for a suspected event, DCRI CEC
will make 2 attempts to gain resolution of the request for
information from the sites. If additional information is not
available for an end point, the site will note that on the
request form and that information will be provided in the
event packet. If additional information is received after
the adjudication has been completed that might affect the
adjudication result, the event will be re-reviewed. The
CEC adjudication form and database will be subsequently
updated to reflect any changes to the initial adjudication.
The DCRI will accept documents that are not in English.
Duke Clinical Research Institute will contract with an
independent vendor for translation services.
4.2.1. Source documents. Duke Clinical Research Institute
received from GSK source documents used in event
adjudication by the original RECORD Clinical Endpoints
Committee. The specific documents that were requested
are outlined below:
• Death—for patients who died during the RECORD
study:
◦ Death in hospital:
• Death summary or
• Investigator narrative
• Autopsy report if available
◦ Death out-of-hospital:
• Narrative of investigator
• Autopsy Report if available
• Police report/family records/whatever docu-
ments could be provided to clarify the
circumstances
• Hospitalization—a hospital discharge letter, or a
narrative about the hospital stay from the
investigator
◦ Hospitalization for Acute MI
• Hospital discharge summary including the results
of the patient's ECG(s) taken during the hospital
admission and results of cardiac biomarker
laboratory tests.
• If the hospital discharge summary was lacking
ECG and enzyme details, a hardcopy of the ECG
plus a hardcopy of the cardiac biomarker results
were required. If a hard copy of the cardiac
biomarker results was not available, the investi-
gator had to complete the MI/Unstable Angina
end point form (section Cardiac Biomarkers).
◦ Hospitalization for Stroke
• Hospital discharge summary with results of a
neurologist’s investigations provided in the dis-
charge summary. If the discharge summary did
not provide sufficient detail, the translated
neurological report was requested. If the neuro-
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summarized a verbal account from the neurolo-
gist in the end point CRF pages for stroke and
transient ischemic attack (TIA).For new events identified by the DCRI RECORD CEC
Group, the following source documents are recommended:
• Death events:
◦ Death summary
◦ Investigator narrative
◦ Autopsy report if available
• MI events:
◦ Hospital discharge summary
◦ Hardcopies of baseline and at least 2 event ECGs
◦ Cardiac biomarker laboratory tests, including units
and reference ranges
• Stroke events
◦ Investigator narrative
◦ Hospital discharge summary
◦ Imaging study reports (magnetic resonance imag-
ing/magnetic resonance angiography, computed
tomography/computed tomography angiography)
◦ Neurology consult notes
If all recommended source documents are not present
and cannot be obtained from the site through the process
described in Section 4.2, the event will be sent for
adjudication with the available documentation.
4.3. CEC adjudication. The DCRI RECORD CEC
physicians will adjudicate each suspected event using the
prespecified end point criteria based on the preponder-
ance of the evidence and clinical knowledge and
experience. All events will be reviewed using the original
RECORDClinical Endpoints Committee definitions and the
new definitions based on the FDA definitions (FDA
Standardized Definitions for End Point Events in Cardio-
vascular Trials).
Potential events triggered from an adverse event term
with no hospitalization or source documentation present
will be reviewed by a single clinician (RECORD CEC
coordinator or physician). The clinician will review the
data present to determine whether or not a potential
event occurred. If there are no data to support that an
event occurred, a RECORD CEC Adjudication Form will
be completed indicating no event. If there are data
present to indicate that an event may have occurred, the
event packet and data will be forwarded to phase I review
for potential MI events and neurologist/phase II review
for potential stroke events.
Phase I review is defined as a process whereby 2
physicians independently adjudicate each suspected event
using the event criteria. The physicians will review each
event using both the original RECORD Clinical Endpoints
Committee definitions and the new definitions concur-
rently for all causes of death. Myocardial infarction events
will be reviewed with a different strategy whereby 2physicians will review each MI event independently using
the original definitions, and a different set of 2 physicians
will review the same MI event with the new definitions.
All events are assigned randomly to the RECORD CEC
physician reviewers. The physicians will adjudicate
suspected events using documentation from the CRF
and available supporting source documentation. If there
is insufficient documentation to determine whether an
event occurred or to determine the specific classification,
the CEC reviewer may ask for additional information or
source documentation. In the event that 1 of the 2
reviewers requests additional information or source
documentation, data or documents that have been
obtained will be distributed to both reviewers.
If the phase I reviewers agree in their adjudication of
the suspected event, the end point classification is
complete. The final adjudication results are recorded on
the RECORD CEC adjudication form and are entered into
the DCRI RECORD CEC adjudication eCRF by the CEC
clinical data assistant or designee. If the phase I reviewers
do not agree regarding the classification of the suspected
event, the event is adjudicated by phase II review.
Phase II review is a process whereby an Adjudication
Committee meeting is organized comprising at least 3
faculty physicians. All disagreements from the phase I
review process will be presented at the Adjudication
Committee meeting of faculty members, and each event
will be reviewed and a decision made by consensus of the
phase II reviewers. If an event is classified as a
“nonevent,” the rationale for calling it a “nonevent” will
be documented on the adjudication form.
If the committee requests additional information or
source documentation, then the event will be reviewed
once the documentation has been obtained. The final
adjudication results are recorded on a RECORD CEC
adjudication form and are entered into the DCRI RECORD
CEC adjudication eCRF by the CEC clinical data assistant
or designee.
All suspected stroke events will be classified based on
original RECORD Clinical Endpoints Committee defini-
tions and the new definitions. All suspected strokes will
be adjudicated by one of the following methods (see CEC
process flow):
• Phase II committee of at least 3 RECORD CEC
physicians, including a neurologist
• Initial review by neurologist, then review by phase II
committee of at least 3 RECORD CEC physicians,
including a neurologist
• Initial review by neurologist, then review by phase II
committee of at least 3 RECORD CEC physicians,
excluding neurologist. If there is a disagreement
between the neurologist and the phase II committee
members, the event will be re-reviewed by a phase II
committee, which will consist of at least 3 RECORD
CEC physicians, including a neurologist.
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RECORD CEC adjudication form and are entered into
the DCRI RECORD CEC adjudication eCRF by the CEC
clinical data assistant or designee.
The DCRI CEC coordinator and chairperson will
determine the need for and timing of meetings of the
Phase II CEC Committee. The CEC physicians will have
an initial face-to-face training meeting. In addition, the
members of the CEC will have face-to-face meetings
and/or conference calls to adjudicate events where
there was a disagreement, to perform quality control
(QC) review of events, and to adjudicate difficult
events. During these meetings, the CEC committee
will assess and refine processes and clarify the
approach to review and adjudication of complex
suspected end points. Minutes of the meetings will be
taken by the CEC coordinator or designee. Minutes
consist of a listing of events, events adjudicated, and
attendance log.
4.4. Quality control
4.4.1. Quality control of the readjudication process. A random sample
of adjudicated events will be reviewed for quality by the
RECORD CEC group. The CEC QC plan is based on the
historical strategy of including a 5% random sample of the
total number of adjudicated events, ensuring a sample
large enough to have the number = [square root (total
number of cases)] + 1. The random sample(s) is(are)
generated by the DCRI trial statistician. The sample of
events is weighted more heavily toward the earlier part of
the study. The initial random sample is generated after
there are 50 adjudicated events in the database.
Additional random samples will be generated after the
first 100, 200, and 300 mortality events are adjudicated.
The same approach will be used for the MI and stroke
events. A sample will be generated after 100, 200, and
300 MI or stroke events are completed.
The events selected are reviewed by RECORD CEC
physicians who are blinded to the original adjudicated
result. The results of the QC review are compared with
the original adjudication result. These results are summa-
rized and reviewed by the RECORD CEC chairperson, and
the findings were distributed to all committee members.
A “major” discrepancy occurs when there is a disagree-
ment as to whether an event did, or did not, occur. A
“minor” discrepancy occurs when there was agreement
on whether an event occurred, but disagreement on the
date, time, type, or evidence. Potential actions based on
the results of the QC review include continuing the CEC
process without modifications, readjudication of events
via the CEC process, modifying the CEC process with
additional QC review, and additional CEC reviewer
training or removal/replacement of a CEC member per
CEC chairperson. A summary report is generated by the
CEC coordinator after each QC review with the findings
detailed to the CEC chairperson/director. Decisions
regarding the CEC process, including a recommendationof changing the original result to that of the QC review,
are made based on the QC results.
4.4.2. Quality control of the manual trigger program. A random
sample of the documents that were screened during
the manual trigger procedures will be rescreened to
ensure the quality of the manual procedures. The QC
process will include having a RECORD CEC physi-
cian rescreen the same documents that were
screened by the RECORD CEC coordinators using
the following metrics:
• 5% of the documents screened by the CEC
coordinator will be reviewed by a physician
• 5% of manual triggers not previously reviewed in
above QC effort will be reviewed by a physician
• 5% of subjects not triggered for an end point event
will be selected for above QC effo1rt
5.0. Event criteria
See Appendices C and D for event definitions.
6.0. Documentation
The following guidelines should be followed for
retention of Clinical Endpoints Committee documents:
• CEC will maintain event packets for each suspected
event, including query correspondence with site,
source documents, and adjudication forms during
the trial. Event packets will be collated by subject
number and kept in a secure, locked file.
• At the end of the readjudication effort, the complete
event packet, including CRF pages, adjudication
forms, source documents, and queries, will be sent
to the sponsor for archiving.
7. CEC process flow
See Figures 1 and 2.
Appendix B. RECORD reevaluation CEC
trigger specifications
This appendix provides the details and process of how
subjects with suspected end point events, including death,
stroke, and MI, will be identified for CEC review in the
RECORD CEC Reevaluation Trial.
Suspected events for review will be identified (or
“triggered”) by an electronic and manual review of the
clinical data captured on the CRF. This initial set of
“triggers” described in this document are based on
extensive review of the protocol, CRF, and incorporation
of CEC experience in prior trials. However, the develop-
ment of clinical trial triggers is best viewed as an iterative
process. If potential changes in the triggers are identified
after cases have been reviewed, the triggers may be
revised during the course of the trial with input from the
clinical leadership, data management, and statistical
teams as appropriate.
Appendix Table I. RECORD Reevaluation CEC electronic trigger specifications
Trigger Form Item Logic English
Death ACE_P1 OUTCOME (Trigger if POPFLAG.PNRAND = Y
and ACE_P1.AE is not null and
ACE_P1.OUTCOME = 3 and VISIT
not in(VISIT 1, VISIT2))
Fire a trigger if the AE form has been
completed and Outcome is DiedPATEND_P1 SERCOD
OR
ORDIED_P1 PATSUB
(Trigger if POPFLAG.PNRAND = Y
and ACE_P1.AE is not null and
ACE_P1.SERCOD3 = '1' and VISIT
not in(VISIT 1, VISIT2))
Fire a trigger if the Serious Adverse
Experience reason is “Fatal”
TRACKWD_P1 DISCODE2
OR
OR
SURVIVAL_P1 DCAUSE
(Trigger if POPFLAG.PNRAND = Y
and PATEND_P1.PATSUB = '2'
and PATEND_P1.DISCODE2 = 1
and VISIT not in(VISIT 1, VISIT2))
Fire a trigger Study if the
Continuation/Withdrawal form indicates
that “Patient is withdrawing completely
from the study” and the reason was
“Fatal Adverse Experience”
SURVIVAL_3rd_P1 AE
OR
OR
SUC_CONT
(Trigger if POPFLAG.PNRAND = Y
and any(DIED_P1.DEATHTXT,
DIED_P1.DEATHDAT,
DIED_P1.ANSYN) is not null and
VISIT not in(VISIT 1, VISIT2))
Fire a trigger if Form D has any
data on it
DIEDD_DT
OR
OR
Q_DIEDD_CH
(Trigger if POPFLAG.PNRAND = Y
and ACE_P1.PREF like any in AE
PREFERRED TERM DEATH list
where Flag = 3 (see next tab in
spec) and VISIT not in(VISIT 1,
VISIT2))
Fire a trigger if a Preferred Term matches
any of those contained in the AE
PREFERRED TERM DEATH listing
PATSTAT
OR
OR
APDTH_DT
(Trigger if POPFLAG.PNRAND =
Y and TRACKWD_P1.SUC_
CONT = "D" or TRACKWD_
P1.NOCNTRSN="PD" or
TRACKWD_P1.DIEDD_DT
is not null or TRACKWD_P1.Q_
DIEDD_CH is not null and
VISIT not in(VISIT 1, VISIT2))
Fire a trigger if the Tracking Form for
Completely Withdrawn Patients
indicates that a completely
withdrawn patient is reported dead
Q_APDTH_CH
OR
OR
CAUSEDTH
(Trigger if POPFLAG.PNRAND = Y
and SURVIVAL_P1.PATSTAT = '2'
or SURVIVAL_P1.DIEDD_DT is not
null or SURVIVAL_P1.Q_
DIEDD_CH is not null or SURVIVAL_
P1.CAUSEDTH is not null and VISIT
not in(VISIT 1, VISIT2))
Fire a trigger if the Survival Status Form
indicates that a patient
is dead at final contact
OR
OR
(Trigger if POPFLAG.PNRAND = Y
and any(SURVIVAL_3RD_P1.DIED_DT,
SURVIVAL_3RD_P1.Q_DIEDD_CH,
SURVIVAL_3RD_P1.APDTH_DT,
SURVIVAL_3RD_P1.Q_APDTH_CH,
SURVIVAL_3RD_P1.CAUSEDTH,
SURVIVAL_3RD_P1.DEATHSC) is not
null and VISIT not in(VISIT 1, VISIT2))
Fire a trigger if the Documentation of
Third Party Survival Data Form
has any indication of death
MI CVPAMPEP_P1 CVAMPRSN (Trigger if POPFLAG.PNRAND = Y
and CVPAMPEP_P1.ICP_T in(1, 2)
and CVPAMPEP_P1.ICP_ART = 1
and VISIT not in(VISIT 1, VISIT2))
Fire a trigger if the Invasive Cardiovascular
Procedure/Amputation end point form
specifies the type of procedure was
Surgical or Nonsurgical and the artery
in which the procedure was performed
was indicated as Coronary
ACE_P1 AE
OR
OR
ECGINT_P1 CHANGEYN
(Trigger if POPFLAG.PNRAND = Y
and ACE_P1.PREF like any in AE
PREFERRED TERM MI list where
Flag = 1 (see next tab in spec)
and VISIT not in(VISIT 1, VISIT2))
Fire a trigger if a Preferred Term matches
any of those contained in the AE
PREFERRED TERM listing
ANYYN
(continued on next page)
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Trigger Form Item Logic English
Stroke ACE_P1 AE Trigger if POPFLAG.PNRAND = Y
and ACE_P1.PREF like any in AE
PREFERRED TERM STROKE list where
Flag = 2 (see next tab in spec) and
VISIT not in(VISIT 1, VISIT2)
Fire a trigger if a Preferred Term matches
any of those contained in the AE
PREFERRED TERM listing
OR
Fire a trigger if Invasive Cardiovascular
Procedure/Amputation end point form
specifies that type of procedure was
Surgical or Nonsurgical and the artery in
which the procedure was performed was
indicated as Carotid
Trigger if POPFLAG.PNRAND = Y
and CVPAMPEP_P1.ICP_T in(1, 2)
and CVPAMPEP_P1.ICP_ART = 2
and VISIT not in(VISIT 1, VISIT2)
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See Appendix Table I for detailed specifications.
Death
• Trigger for Death event if Adverse Event (AE) Form
has been completed and Outcome is Died.
• Trigger for Death event if Serious Adverse Experi-
ence (SAE) reason is Fatal.
• Trigger for Death event if Form D (Death Form) has
any data on it
• Trigger for Death event if Study Discontinuation/
Withdrawal Form indicates “Patient is withdrawing
completely from the study,” and the reason is “Fatal
Adverse Experience.”
• Trigger for Death event if AE Form or SAE Form
Preferred Term matches any of those listed on the
Death Preferred Term Listing (Appendix Table II).
• Trigger for a Death event if Tracking Form for
Completely Withdrawn Patients indicates that a
patient is reported dead.
• Trigger for a Death event if Survival Status Form
indicates the patient is dead.
• Trigger for a Death event if Third Party Survival Data
Form indicates that patient has died.
Myocardial infarction (MI)
• Trigger for MI event if Invasive Cardiovascular
Procedure/Amputation Form specifies the type of
procedure as Surgical or Nonsurgical and the artery
indicated is Coronary.
• Trigger for MI event if AE Form or SAE Form
Preferred Term matches any of those listed on the MI
Preferred Term Listing (Appendix Table III).
Stroke
• Trigger for Stroke event if AE Form or SAE Form
Preferred Term matches any of those listed on the
Stroke Preferred Term Listing (Appendix Table IV).• Trigger for Stroke event if Invasive Cardiovascular
Procedure/Amputation Form specifies the type of
procedure as Surgical or Nonsurgical and the artery
indicated is Carotid.
Electronic data listings
The following data listing has been electronically
extracted from the database to identify potential events.
Each data point listed will be screened by a RECORD CEC
clinical trial coordinator to determine if the potential
event requires CEC adjudication. Documentation that the
data have been screened will be maintained on the Data
Listing spreadsheet, along with the CEC trigger number,
for the potential events sent for CEC adjudication.
• Serious Adverse Experiences deleted from database
• Serious Adverse Experiences changed in the
database
• Abnormal ECGs and AE/SAE with onset date ± 14
days of ECG date
• Hospitalization and AE/SAE with onset date ± 14
days of hospital admission date
• Patients who started new cardiac medications
(thrombolytics, intravenous IIb/IIIa inhibitors, and
intravenous heparin) during the study
• Patients who withdrew from Randomized Treatment
phase of the study because of safety risk, admittance
to a long-term health care facility, or other reason
• Patients who withdrew completely from study and
specified “other” reasonManual triggers
The RECORD CEC clinical trial coordinators will
perform a manual review of paper documents for each
subject to identify potential events. Documentation that
the paper sources were manually screened will be
maintained via spreadsheet listing all enrolled subjects.
Paper sources that the CEC coordinators will review
include, but are not limited to, the following:
Appendix Table II. Death AE/SAE preferred terms
Flag: 3 = death Preferred term
3 Cardiac arrest
3 Brain death
3 Death
3 Drowning
3 Multiorgan failure
3 Sudden cardiac death
3 Sudden death
3 Intentional overdose
3 Overdose
3 Road traffic accident
3 Completed suicide
3 Asphyxia
3 Respiratory failure
3 Cardiac fibrillation
3 Appendicitis perforated
3 Diverticular perforation
3 Duodenal perforation
3 Food poisoning
Lopes et al 216.e9
American Heart Journal
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• Hospitalization or Accident and Emergency Depart-
ment Visit End Point Form
• Source documents
• AE and SAE Forms (containing investigator verbatim
terms)
• All Endpoints that were sent to original RECORD
Clinical End Point Committee
• Death End Point Forms
• MI/Unstable Angina End Point Forms
• Stroke/TIA End Point Forms
• Hospitalizations
• Survival Status Forms
• Third Party Survival Data Forms
• Tracking Forms for Completely Withdrawn Patients
• Study Completion Forms
• Concomitant Medication Forms3 Gastric ulcer perforation
3 Intestinal perforation
3 Peptic ulcer perforation
3 Peritonitis
3 Anaphylactic reaction
3 Meningitis viral
3 Accidental overdose
3 Wound dehiscence
3 Adenocarcinoma
3 Breast cancer metastatic
3 Colon cancer stage iii
3 Hepatic cancer metastatic
3 Lung cancer metastatic
3 Metastases to abdominal cavity
3 Metastases to bone
3 Metastases to breast
3 Metastases to central nervous system
3 Metastases to liver
3 Metastases to lung
3 Metastases to lymph nodes
3 Metastases to peritoneum
3 Metastases to spine
3 Metastatic malignant melanoma
3 Metastatic neoplasm
3 Metastatic renal cell carcinoma
3 Ovarian cancer metastatic
3 Pancreatic carcinoma
3 Pancreatic carcinoma stage IV
3 Rectal cancer metastatic
3 Suicide attempt
3 Bladder perforation
3 Choking
3 Pulmonary embolism
3 Respiratory distress
3 Aortic aneurysm rupture
3 Hypovolaemic shock
3 Shock hemorrhagicAppendix C. Original RECORD end point
definitions
Death
1.0. Definition of cardiovascular death end points.
Cardiovascular death shall be defined as any death for
which an unequivocal noncardiovascular cause cannot
be established. Cardiovascular death will include death
after heart failure, death after acute MI, sudden death, and
death due to acute vascular events. Deaths that are due to
unknown causes (and therefore cannot be categorized
into the categories listed below) will be classified as
“unknown deaths” but will be counted as cardiovascular
deaths for the analysis of the “primary end point.”
1.1. Death after heart failure. This is defined as death due to the
onset and progression of symptoms defining definite
heart failure (as listed in the present charter).
1.2. Death after MI. This is defined as death within 30 days
after acute MI.
1.3. Sudden death. This is defined as death due to one of the
following reasons:
• within 1 hour after onset of new symptoms
• witnessed death, without new symptoms occurring
within 72 hours preceding death
• cardiac arrest followed by death within 30 days even
if temporarily recovered
• unwitnessed death in the absence of new symptoms*
1.4. Death due to acute vascular events. This is defined as death due
to aortic dissection, aortic aneurysm, pulmonary embo-
lism, stroke, or any other vascular cause.* The premise for the death to be adjudicated in this category is
that it is known that the patients did not have any signs or
symptoms 24 hours before the death occurred; otherwise, it will
constitute a death of unknown cause.Myocardial Infarction
2.0. Hospitalization for acute MI. Acute MI will be
adjudicated according to the definition in the document:
“myocardial infarction redefined—a consensus document
of The Joint European Society of Cardiology/American
Appendix Table III. MI AE/SAE preferred terms
Flag: 1 = MI Preferred term
1 Acute coronary syndrome
1 Acute MI
1 Angina pectoris
1 Angina unstable
1 Arteriosclerosis coronary artery
1 Atrioventricular block complete
1 Bundle-branch block left
1 Cardiac aneurysm
1 Cardiac discomfort
1 Cardiac disorder
1 Cardiac failure
1 Cardiac failure acute
1 Cardiac failure congestive
1 Cardiomegaly
1 Cardiomyopathy
1 Cardiovascular disorder
1 Coronary artery disease
1 Coronary artery insufficiency
1 Coronary artery occlusion
1 Coronary artery stenosis
1 Ischemic cardiomyopathy
1 Myocardial fibrosis
1 Myocardial ischemia
1 Postinfarction angina
1 Prinzmetal angina
1 Silent MI
1 Ventricular dysfunction
1 Ventricular fibrillation
1 Ventricular tachycardia
1 Chest discomfort
1 Chest pain
1 Pain
1 Myocardiac abscess
1 Cardiac procedure complication
1 Cardiac valve replacement complication
1 In-stent arterial restenosis
1 Stent occlusion
1 Blood creatine phosphokinase increased
1 Cardiac stress test
1 ECG signs of myocardial ischemia
1 Electrocardiogram abnormal
1 Electrocardiogram change
1 Electrocardiogram low voltage
1 Electrocardiogram Q waves
1 Electrocardiogram ST segment abnormal
1 Electrocardiogram ST segment depression
1 Electrocardiogram ST segment elevation
1 Electrocardiogram ST-T change
1 Electrocardiogram T wave abnormal
1 Electrocardiogram T wave inversion
1 Exercise electrocardiogram abnormal
1 Acute pulmonary edema
1 Dyspnea at rest
1 Dyspnea exertional
1 Dyspnea paroxysmal nocturnal
1 Nocturnal dyspnea
1 Orthopnea
1 Arterial occlusive disease
1 Cardiovascular insufficiency
1 Circulatory collapse
1 Ischemia
1 Shock
Appendix Table III (continued)
Flag: 1 = MI Preferred term
1 Arrhythmia
1 Atrioventricular block
1 Atrioventricular block second degree
1 Bradyarrhythmia
1 Bradycardia
1 Bundle-branch block
1 Bundle-branch block bilateral
1 Bundle-branch block right
1 Congestive cardiomyopathy
1 Left ventricular failure
1 Right ventricular failure
1 Sinus bradycardia
1 Tachyarrhythmia
1 Tachycardia
1 Ventricular arrhythmia
1 Generalized edema
1 Pulmonary edema
1 Arterial stenosis
1 MI
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Myocardial Infarction;5
Hospitalization plus biochemical markers as defined
below:
Elevation of cardiac biomarkers troponin I and/or
troponin T above ULN or CK-MB isoenzyme ≥2× ULN
or creatine kinase (CK) N 2× ULN.
Plus one of the following:
(i) Typical symptoms of cardiac ischemia
(ii) New pathological electrocardiogram findings as
defined in Eur Heart J 2000;21:1502–135
Stroke
3.1. Hospitalization for stroke. Whenever possible
the disease should be confirmed by a neurologist or by
computed tomography or magnetic resonance imaging.
Hospitalization plus:
Rapidly developed clinical signs of focal (or global [global
applies to patients with subarachnoid hemorrhage or deep
coma but excluding coma of systemic vascular origin such
as shock, Stokes-Adams syndrome, or hypertensive en-
cephalopathy]) disturbance of cerebral function lasting
more than 24 hours (unless interrupted by thrombolysis,
surgery, or death), with no apparent cause other than a
vascular origin: it includes patients presenting clinical signs
and symptoms suggestive of subarachnoid hemorrhage,
intracerebral hemorrhage, or cerebral ischemic necrosis.
Secondary stroke events resulting from blood diseases
(eg, leukemia, polycythemia vera), as well as stroke
symptoms from brain tumors or brain metastases, should
be excluded. Secondary stroke caused by trauma and other
disorders (eg, metabolic disturbance) or peripheral lesion
that could cause a localizing neurologic deficit or coma
should also be excluded.
Definite focal signs:
Appendix Table IV. Stroke AE/SAE preferred terms
Flag: 2 = stroke Preferred term
2 Deafness
2 Deafness bilateral
2 Deafness neurosensory
2 Deafness unilateral
2 Vestibular ataxia
2 Blindness
2 Diplopia
2 Retinal infarction
2 Retinal ischemia
2 Retinal vascular thrombosis
2 Retinal vein occlusion
2 Retinal vein thrombosis
2 Dysphagia
2 Gait disturbance
2 Brain contusion
2 Concussion
2 Head injury
2 Traumatic brain injury
2 Carotid bruit
2 Aphasia
2 Ataxia
2 Balance disorder
2 Carotid arteriosclerosis
2 Carotid artery stenosis
2 Cerebral infarction
2 Cerebral venous thrombosis
2 Cerebrovascular accident
2 Cerebrovascular disorder
2 Cerebrovascular insufficiency
2 Coordination abnormal
2 Dysarthria
2 Dysphasia
2 Hemiparesis
2 Hemiplegia
2 Hypokinesia
2 Hypotonia
2 Ischemic cerebral infarction
2 Ischemic stroke
2 Lacunar infarction
2 Paralysis
2 Transient ischemic attack
2 Vertebrobasilar insufficiency
2 Subdural hematoma
2 Brain edema
2 Cerebral hemorrhage
2 Cerebral ischemia
2 Hemorrhage intracranial
2 Hemorrhagic stroke
2 Intracranial hematoma
2 Ruptured cerebral aneurysm
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dyscoordination)
• Unilateral or bilateral sensory impairment
• Aphasia/dysphasia (nonfluent speech)
• Hemianopia (half-sided impairment of visual fields)
• Diplopia
• Forced gaze (conjugate deviation)
• Dysphagia of acute onset
• Apraxia of acute onset
• Ataxia of acute onset
• Perception deficit of acute onsetNot acceptable as sole evidence of focal dysfunction:
• Dizziness, vertigo
• Localized headache
• Blurred vision of both eyes
• Dysarthria (slurred speech)
• Impaired cognitive function (including confusion)
• Impaired consciousness
• Seizures
(Although strokes can present in this way, these signs
are not specific and cannot therefore be accepted as
definite evidence for stroke.)
Appendix D. FDA end point definitions
Death
The determination of the specific cause of cardiovas-
cular death is complicated by the fact that we are
particularly interested in one underlying cause of death
(acute MI [AMI]) and several modes of death (arrhythmia
and heart failure/low output). It is noted that heart
attack–related deaths are manifested as sudden death or
heart failure, so these events need to be carefully defined.
Cardiovascular death includes death resulting from
an AMI, sudden cardiac death, death due to heart failure,
death due to stroke, and death due to other cardiovas-
cular causes, as follows:
1. Death due to Acute MI refers to a death by any
mechanism (arrhythmia, heart failure, low output)
within 30 days after an MI related to the immediate
consequences of theMI, such as progressive congestive
heart failure (CHF), inadequate cardiac output, or
recalcitrant arrhythmia. If these events occur after a
“break” (eg, a CHF- and arrhythmia-free period of at
least a week), they should be designated by the
immediate cause, although the MI may have increased
the risk of that event (eg, late arrhythmic death
becomes more likely after an AMI). The AMI should
be verified to the extent possible by the diagnostic
criteria outlined for AMI or by autopsy findings showing
recentMI or recent coronary thrombus. Sudden cardiac
death, if accompanied by symptoms suggestive of
myocardial ischemia, new ST elevation, new left
bundle-branch block, or evidence of fresh thrombus
by coronary angiography and/or at autopsy, should be
considered death resulting from an acute MI, even if
death occurs before blood samples or 12-lead electro-
cardiogram (ECG) could be obtained, or at a time before
the appearance of cardiac biomarkers in the blood.
Death resulting from a procedure to treat an MI
(percutaneous coronary intervention [PCI], coronary
artery bypass graft surgery [CABG]), or to treat a
complication resulting fromMI, should also be considered
death due to acute MI.
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ischemia (angina) or death due to an MI that occurs as a
direct consequence of a cardiovascular investigation/
procedure/operation should be considered as a death due
to other cardiovascular causes.
2. Sudden cardiac death refers to a death that occurs
unexpectedly, not following an AMI, and includes the
following deaths:
• Death witnessed and instantaneous without new or
worsening symptoms
• Death witnessed within 60 minutes of the onset of
new or worsening cardiac symptoms, unless the
symptoms suggest AMI
• Death witnessed and attributed to an identified
arrhythmia (eg, captured on an ECG recording,
witnessed on a monitor, or unwitnessed but found
on implantable cardioverter-defibrillator review)
• Death after unsuccessful resuscitation from cardiac
arrest
• Death after successful resuscitation from cardiac
arrest and without identification of a noncardiac
etiology (postcardiac arrest syndrome)
• Unwitnessed death without other cause of death
(information regarding the patient's clinical status
preceding death should be provided, if available)
General considerations
• A subject seen alive and clinically stable 12 to 24
hours before being found dead without any
evidence or information of a specific cause of
death should be classified as “sudden cardiac
death.” Typical scenarios include the following:
◦ Subject well the previous day but found dead in
bed the next day
◦ Subject found dead at home on the couch with the
television on
• Deaths for which there is no information beyond
“Patient found dead at home” may be classified as
“death due to other cardiovascular causes” or in
some trials, “undetermined cause of death.” Please
see “Definition of Undetermined Cause of Death”
section below for full details.
3. Death due to heart failure or cardiogenic shock
refers to a death occurring in the context of clinically
worsening symptoms and/or signs of heart failure
without evidence of another cause of death and not
after an AMI. Note that deaths due to heart failure can
have various etiologies, including 1 or more AMIs (late
effect), ischemic or nonischemic cardiomyopathy, or
valve disease.
Death due to heart failure or cardiogenic shock should
include sudden death occurring during an admission forworsening heart failure as well as death from progressive
heart failure or cardiogenic shock after implantation of a
mechanical assist device. New or worsening signs and/or
symptoms of CHF include any of the following:
a. New or increasing symptoms and/or signs of heart
failure requiring the initiation of, or an increase in,
treatment directed at heart failure or occurring in a
patient already receiving maximal therapy for heart
failure
b. Heart failure symptoms or signs requiring continuous
intravenous therapy or chronic oxygen administration
for hypoxia caused by pulmonary edema
c. Confinement to bed predominantly caused by heart
failure symptoms
d. Pulmonary edema sufficient to cause tachypnea and
distress not occurring in the context of an acute MI or
worsening renal function, or as the consequence of an
arrhythmia occurring in the absence of worsening
heart failure
e. Cardiogenic shock not occurring in the context of an
AMI or as the consequence of an arrhythmia occurring
in the absence of worsening heart failure
Cardiogenic shock is defined as systolic blood pressure
is b90 mm Hg for greater than 1 hour, not responsive to
fluid resuscitation and/or heart rate correction, and felt to
be secondary to cardiac dysfunction and associated with
at least one of the following signs of hypoperfusion:
• Cool, clammy skin or
• Oliguria (urine output b30 mL/h) or
• Altered sensorium or
• Cardiac index b 2.2 L min−1 m−2
Cardiogenic shock can also be defined if systolic
blood pressure is b90 mm Hg and increases to ≥90 mm
Hg in less than 1 hour with positive inotropic or
vasopressor agents alone and/or with mechanical
support.
General considerations
Heart failure may have a number of underlying causes
including acute or chronic ischemia, structural heart
disease (eg, hypertrophic cardiomyopathy), and valvular
heart disease. Where treatments are likely to have specific
effects and it is likely to be possible to distinguish
between the various causes, then it may be reasonable to
separate out the relevant treatment effects. For example,
obesity drugs such as fenfluramine (pondimin) and
dexfenfluramine (redux) were found to be associated
with the development of valvular heart disease and
pulmonary hypertension. In other cases, the aggregation
implied by the definition above may bemore appropriate.
4. Death due to stroke refers to death occurring up to 30
days after a stroke that is either caused by the stroke or
caused by a complication of the stroke.
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cardiovascular death not included in the above
categories (eg, dysrhythmia unrelated to sudden
cardiac death, pulmonary embolism, cardiovascular
intervention [other than one related to an AMI],
aortic aneurysm rupture, or peripheral arterial dis-
ease). Mortal complications of cardiac surgery or
nonsurgical revascularization should be classified as
cardiovascular deaths.
Definition of noncardiovascular death. Noncar-
diovascular death is defined as any death that is not
thought to be due to a cardiovascular cause. Detailed
recommendations on the classification of noncardiovas-
cular causes of death are beyond the scope of this
document. The level of detail required and the optimum
classification will depend on the nature of the study
population and the anticipated number and type of
noncardiovascular deaths. Any specific anticipated safety
concern should be included as a separate cause of death.
The following is a suggested list of noncardiovascular**
causes of death:
Nonmalignant causes
• Pulmonary
• Renal
• Gastrointestinal
• Hepatobiliary
• Pancreatic
• Infection (includes sepsis)
• Noninfectious (eg, systemic inflammatory response
syndrome)
• Hemorrhage, not intracranial
• Noncardiovascular system organ failure (eg, hepatic
failure)
• Noncardiovascular surgery
• Other noncardiovascular, specify: _______________
• Accidental/trauma
• Suicide
• Drug overdose
Malignant causes
Malignancy should be coded as the cause of death if:
• death results directly from the cancer; or
• death results from a complication of the cancer (eg,
infection, complication of surgery/chemotherapy/
radiotherapy); or
• death results from withdrawal of other therapies
because of concerns relating to the poor prognosis
associated with the cancer.
Cancer deaths may arise from cancers that were present
before randomization or which developed subsequently.
It may be helpful to distinguish these 2 scenarios (ie,
worsening of prior malignancy, new malignancy).** Death due to a gastrointestinal bleed should not be considered a
cardiovascular death.Suggested categorization includes common organ
systems, hematologic, or unknown.
Definition of undetermined cause of death. Un-
determined cause of death refers to a death not
attributable to one of the above categories of cardiovas-
cular death or to a noncardiovascular cause. Inability to
classify the cause of death may be due to lack of
information (eg, the only available information is “patient
died”) or when there is insufficient supporting informa-
tion or detail to assign the cause of death. In general, the
use of this category of death should be discouraged and
should apply to a minimal number of patients in well-run
clinical trials.
A common analytic approach for cause of death
analyses is to assume that all undetermined cases are
included in the cardiovascular category (eg, presumed
cardiovascular death, specifically “death due to other
cardiovascular causes”). Nevertheless, the appropriate
classification and analysis of undetermined causes of
death depend on the population, the intervention under
investigation, and the disease process. The approach
should be prespecified and described in the protocol and
other trial documentation such as the end point
adjudication procedures and/or the SAP.
Myocardial infarction
1. General considerations. The term MI should be used when
there is evidence of myocardial necrosis in a clinical
setting consistent with myocardial ischemia.
In general, the diagnosis of MI requires the combination of:
• evidence of myocardial necrosis (either changes in
cardiac biomarkers or postmortem pathological
findings); and
• supporting information derived from the clinical
presentation, ECG changes, or the results of
myocardial or coronary artery imaging.
The totality of the clinical, ECG, and cardiac biomarker
information should be considered to determine whether
or not an MI has occurred. Specifically, timing and trends
in cardiac biomarkers and ECG information require
careful analysis. The adjudication of MI should also take
into account the clinical setting in which the event
occurs. Myocardial infarction may be adjudicated for an
event that has characteristics of an MI but which does not
meet the strict definition because biomarker or ECG
results are not available.
2. Criteria for MI.
a. Clinical presentation
The clinical presentation should be consistent with
diagnosis of myocardial ischemia and infarction. Other
findings that might support the diagnosis of MI should
be taken into account because a number of conditions
are associated with elevations in cardiac biomarkers
(eg, trauma, surgery, pacing, ablation, congestive heart
failure, hypertrophic cardiomyopathy, pulmonary
† If biomarkers are increasing or peak is not reached, then a
efinite diagnosis of recurrent MI is generally not possible.
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subarachnoid hemorrhage, infiltrative and inflamma-
tory disorders of cardiac muscle, drug toxicity, burns,
critical illness, extreme exertion, and chronic kidney
disease). Supporting information can also be consid-
ered from myocardial imaging and coronary imaging.
The totality of the data may help differentiate acute MI
from the background disease process.
b. Biomarker elevations
For cardiac biomarkers, laboratories should report an
upper reference limit (URL). If the 99th percentile of
the URL from the respective laboratory performing the
assay is not available, then the URL for myocardial
necrosis from the laboratory should be used. If the 99th
percentile of the URL or the URL for myocardial
necrosis is not available, the MI decision limit for the
particular laboratory should be used as the URL.
Laboratories can also report both the 99th percentile
of the upper reference limit and the MI decision limit.
Reference limits from the laboratory performing the
assay are preferred over the manufacturer's listed
reference limits in an assay's instructions for use.
Creatine kinase-MB (CK-MB) and troponin are pre-
ferred, but CK may be used in the absence of CK-MB
and troponin.
For MI subtypes, different biomarker elevations for CK,
CK-MB, or troponin will be required. The specific
criteria will be referenced to the URL.
In many studies, particularly those in which patients
present acutely to hospitals which are not participating
sites, it is not practical to stipulate the use of a single
biomarker or assay, and the locally available results are
to be used as the basis for adjudication. However, if
possible, using the same cardiac biomarker assay, and
preferably a core laboratory, for all measurements
reduces interassay variability.
Because the prognostic significance of different types of
MIs (eg, periprocedural MI versus spontaneous MI) may
be different, consider evaluating outcomes for these
subsets of patients separately.
c. ECG changes
Electrocardiographic changes can be used to support
or confirm an MI. Supporting evidence may be
ischemic changes, and confirmatory information may
be new Q waves:
• Criteria for acute myocardial ischemia (in the
absence of left ventricular hypertrophy and left
bundle-branch block)
◦ ST elevation
New ST elevation at the J point in 2 anatomically
contiguous leads with the cutoff points ≥0.2 mV
in men (N0.25 mV in men younger than 40 years)
or ≥0.15 mV in women in leads V2 to V3 and/or
≥0.1 mV in other leads
◦ ST depression and T-wave changes
New horizontal or downsloping ST depression≥0.05 mV in 2 contiguous leads, and/or new T
inversion ≥0.1 mV in 2 contiguous leads
The above ECG criteria illustrate patterns consis-
tent with myocardial ischemia. In patients with
abnormal biomarkers, it is recognized that lesser
ECG abnormalities may represent an ischemic
response and may be accepted under the
category of abnormal ECG findings.
• Criteria for pathological Q wave
◦ Any Q wave in leads V2 to V3 ≥0.02 seconds or QS
complex in leads V2 and V3
◦ Q wave ≥0.03 seconds and ≥0.1 mV deep or QS
complex in leads I, II, aVL, aVF, or V4 to V6 in any 2
leads of a contiguous lead grouping (I, aVL, V6; V4-
V6; II, III, and aVF)
The same criteria are used for supplemental leads
V7 to V9 and for the Cabrera frontal plane lead
grouping.
• Criteria for prior MI
◦ Pathological Q waves, as defined above
◦ R wave≥0.04 seconds in V1 to V2 and R/S≥1 with
a concordant positive T wave in the absence of a
conduction defect
3. MI subtypes. Several MI subtypes are commonly reported
in clinical investigations, and each is defined below:
a. Spontaneous MI
1. Detection of rise and/or fall of cardiac biomarkers with
at least 1 value above the URL with at least 1 of the
following:
• Clinical presentation consistent with ischemia
• ECG evidence of acute myocardial ischemia
• New pathological Q waves
• Imaging evidence of new loss of viable myocardium
or new regional wall motion abnormality
• Autopsy evidence of AMI
2. If biomarkers are elevated from a prior infarction, then
a spontaneous MI is defined as follows:
a. One of the following:
◦ Clinical presentation consistent with ischemia
◦ ECG evidence of acute myocardial ischemia
◦ New pathological Q waves
◦ Imaging evidence of new loss of viable myocardi-
um or new regional wall motion abnormality
◦ Autopsy evidence of AMI
AND
b. Both of the following:
◦ Evidence that cardiac biomarker values were
decreasing (eg, 2 samples 3-6 hours apart) before
the suspected MI†
◦ ≥20% increase (and NURL) in troponin or CK-MB
between a measurement made at the time of the
initial presentation and a further sample taken 3 to
6 hours laterd
Types of MI
Treatment A: no.
of patients (N)
Treatment B: no.
of patients (N)
MI type 1 n, % n, %
MI type 2 n, % n, %
MI type 3 n, % n, %
MI type 4 n, % n, %
MI type 5 n, % n, %
Total no. n, % n, %
N, total number of patients; n, number of patients with a particular MI.
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Peri-PCI MI is defined by any of the following criteria.
Symptoms of cardiac ischemia are not required.
1. Biomarker elevations within 48 hours of PCI:
• Troponin or CK-MB (preferred) N 3× URL and
• No evidence that cardiac biomarkers were elevated
before the procedure;
OR
• Both of the following must be true:
◦ ≥50%‡ increase in the cardiac biomarker result
◦ Evidence that cardiac biomarker values were
decreasing (eg, 2 samples 3-6 hours apart) before
the suspected MI
2. New pathological Q waves
3. Autopsy evidence of acute MI
c. Coronary artery bypass grafting–related MI
Peri–coronary artery bypass graft surgery (CABG) MI is
defined by the following criteria. Symptoms of cardiac
ischemia are not required.
1. Biomarker elevations within 72 hours of CABG:
• Troponin or CK-MB (preferred) N 5× URL and
• No evidence that cardiac biomarkers were elevated
before the procedure;
OR
• Both of the following must be true:
◦ ≥50%§ increase in the cardiac biomarker result
◦ Evidence that cardiac biomarker values were
decreasing (eg, 2 samples 3-6 hours apart) before
the suspected MI
AND
2. One of the following:
• New, pathological Qwaves persistent through 30 days
• New, persistent, non–rate-related LBBB
• Angiographically documented new graft or native
coronary artery occlusion
• Other complication in the operating room resulting
in loss of myocardium
• Imaging evidence of new loss of viable myocardium
OR
3. Autopsy evidence of acute MI
d. Silent MI
Silent MI is defined by the following:
1. No evidence of acute MI
AND
2. Any one of the following criteria:
• New pathological Q waves. A confirmatory ECG is
recommended if there have been no clinical
symptoms or history of MI.‡ Data should be collected in such a way that analyses using ≥20%
or ≥50% could both be performed.
§ Data should be collected in such a way that analyses using ≥20%
or ≥50% could both be performed.• Imaging evidence of a region of loss of viable
myocardium that is thinned and fails to contract, in
the absence of a nonischemic cause
• Autopsy evidence of a healed or healing MI
Common classification schemes for MI categories. For some trials,
categorization ofMI endpointsmaybehelpful or necessary
using 1 or more of the classification schemes below:
1. By the universal MI definition:
a. Clinical classification of different types of MI
• Type 1
Spontaneous MI related to ischemia caused by a
primary coronary event such as plaque erosion
and/or rupture, fissuring, or dissection
• Type 2
MI secondary to ischemia caused by either increased
oxygen demand or decreased supply, for example,
coronary artery spasm, coronary embolism, anemia,
arrhythmias, hypertension, or hypotension
• Type 3
Sudden unexpected cardiac death, including car-
diac arrest, often with symptoms suggestive of
myocardial ischemia, accompanied by presumably
new ST elevation, or new LBBB, or evidence of
fresh thrombus in a coronary artery by angiogra-
phy and/or at autopsy, but death occurring before
blood samples could be obtained, or at a time
before the appearance of cardiac biomarkers in
the blood
• Type 4a
MI associated with PCI
• Type 4b
MI associated with stent thrombosis as documented
by angiography or at autopsy
• Type 5
MI associated with CABG
b. Sample clinical trial tabulation of randomized patients
by types of MI2. By electrocardiographic features:
• ST-elevation MI
◦ Additional subcategories may include the follow-
ing the following:
Classification of the different types of MI According to multiples of the 99th percentile URL of the applied cardiac biomarker
The hatched areas represent biomarker elevations below the decision limit used for these types of myocardial infarction.
⁎ Biomarkers are not available for this type of MI because the patients expired before biomarker determination could be performed.
† For the sake of completeness, the total distribution of biomarker values should be reported. The hatched areas represent biomarker elevations
below the decision limit used for these types of MI.\
Scale Disability
0 No symptoms at all
1 No significant disability despite symptoms; able to carry
out all usual duties and activities
2 Slight disability; unable to carry out all previous activities,
but able to look after own affairs without assistance
3 Moderate disability; requiring some help, but able to
walk without assistance
4 Moderately severe disability; unable to walk without
assistance and unable to attend to own bodily needs
without assistance
5 Severe disability; bedridden, incontinent, and
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▪ Non–Q wave
▪ Unknown (no ECG or ECG not interpretable)
• Non–ST-elevation MI
◦ Additional subcategories may include the following:
▪ Q wave
▪ Non–Q wave
▪ Unknown (no ECG or ECG not interpretable)
• Unknown (no ECG or ECG not interpretable)
3. By biomarker elevation (per universal MI definition):
The magnitude of cardiac biomarker elevation can be
calculated as a ratio of the peak biomarker value divided
by the 99th percentile URL.
The biomarker elevation can be provided for various MI
subtypes, as shown in the example below.
Stroke
1. Stroke. Stroke is defined as an acute episode of
neurologic dysfunction caused by focal or global brain,
spinal cord, or retinal vascular injury.
Classification
A. Ischemic stroke
Ischemic stroke is defined as an acute episode of
focal cerebral, spinal, or retinal dysfunction caused
by an infarction of central nervous system tissue.
Hemorrhage may be a consequence of ischemic
stroke. In this situation, the stroke is an ischemic
stroke with hemorrhagic transformation and not a
hemorrhagic stroke.
B. Hemorrhagic stroke
Hemorrhagic stroke is defined as an acute episode
of focal or global cerebral or spinal dysfunction
caused by a nontraumatic intraparenchymal, intra-
ventricular, or subarachnoid hemorrhage.
C. Undetermined stroke
Undetermined stroke is defined as a stroke with
insufficient information to allow categorization as
A or B.
2. Stroke Disability. Stroke disability should be measured by
a reliable and valid scale in all cases. For example, themodified Rankin Scale may be used to address this
requirement.Additional considerations. In trials involving patients with stroke,
evidence of vascular central nervous system injury without
recognized neurologic dysfunction may be observed.
Examples include microhemorrhage, silent infarction,
and silent hemorrhage. When encountered, the clinical
relevance of these findings may be unclear. If appropriate
for a given clinical trial, however, they should be precisely
defined and categorized.
The distinction between a transient ischemic attack and an
ischemic stroke is the presence of infarction, not the
transience of the symptoms. In addition to laboratory
documentation of infarction, persistence of symptoms is an
acceptable indicator of infarction. Thus, symptom transience
should be defined for any clinical trial in which it will be used
to distinguish between transient ischemia and infarction.
requiring constant nursing care and attention
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1. AbbreviationsAbbreviation Definition
CEC Clinical events classification
Cox PH Cox proportional hazard (model)
CV Cardiovascular
CVFU Cardiovascular follow-up
DCRI Duke Clinical Research Institute
FDA US Food and Drug Administration
GSK GlaxoSmithKline
MACE Major adverse cardiac end points
MET Metformin
MI Myocardial infarction
RDTP Randomized dual-treatment phase
RECORD Rosiglitazone Evaluated for Cardiac Outcomes
and Regulation of glycaemia in Diabetes
RSG Rosiglitazone
RTP Randomized treatment phase
SAP Statistical analysis plan
SSFU Survival status follow-up
SU Sulphonylurea2. Introduction
The readjudication/reanalysis of RECORD data is
planned to be done in 2 phases. In the first phase,
DCRI will screen RECORD data to identify deaths and
classify each death according to cause (cardiovascular
[CV], non-CV, or unknown). In the second phase,
possible occurrences of nonfatal MI and nonfatal stroke
will be identified and adjudicated.
This document describes planned statistical analyses of
the first phase (mortality) only.
2.1. Background. The RECORD study was a long-
term, open-label, randomized clinical trial in patients with
type 2 diabetes, comparing the effects of the combination
of rosiglitazone and either metformin or sulphonylurea
with metformin plus sulphonylurea on cardiovascular
end points and glycaemia. The results of RECORD have
been published,2 and study data have been submitted to
the FDA.
Food and Drug Administration review of the RECORD
trial raised questions about the “potential bias in
identification of cardiovascular events due to the
open-label design.”24 The FDA has requested an
independent review of RECORD data and updated
analyses for the specific end points all-cause mortality,
cardiovascular mortality, major adverse cardiac end
points (MACEs), and the individual components of
MACE. GlaxoSmithKline has contracted DCRI to per-
form the independent review.
The Duke Clinical Research Institute plans to perform
the review and readjudication in 2 phases, as described in
DCRI Readjudication Protocol AVD115170 (Version 1.0;
January 28, 2011). The first phase will focus on mortality(all-cause, cardiovascular, and noncardiovascular) end
points, and the second phase will include analysis of the
end points of MI (fatal and nonfatal), stroke (fatal and
nonfatal), and MACE. Appendix I of Protocol AVD115170
contains the initial SAP describing the general approach
to be taken in the analysis of the readjudicated data for
both the first and second phases of the readjudication
effort.
2.2. Analysis of first phase (mortality). This
document is the SAP for the analysis of mortality (all-
cause, cardiovascular, and noncardiovascular) end points
assessed in the DCRI independent review and read-
judication of the data from the RECORD study. It
supersedes the SAP in Appendix I of Protocol
AVD115170 and contains additional details of first
phase analyses described in that document.3. Objectives and operational overview
The independent data review and readjudication will
be carried out in 2 phases. The first phase will consist
of identification and review of all known deaths
reported in the RECORD data package. The CEC will
classify each death as cardiovascular, noncardiovascular,
or unknown and identify the date of death. In addition,
DCRI will use 1 or more algorithms to determine the
date last known alive in patients not reported to have
died. All persons involved in data review and adjudica-
tion will be blinded to randomized treatment arm and
actual treatment administered.
In the second phase, CEC will review, based on
predefined criteria, all suspected incidences of nonfatal
MI or nonfatal stroke and determine whether an MI or
stroke has actually occurred. For patients deemed to have
had an MI or stroke, the CEC will identify the date of the
event. For the end points of MI and stroke, DCRI will use
1 or more algorithms to determine the last known event-
free date in patients deemed not to have experienced an
MI or stroke. All persons involved in data review and
adjudication will be blinded to randomized treatment arm
and actual treatment administered.
Analysis of the 2 phases will be stepwise, with the
mortality results being reported first. This document
describes the analysis of the first phase only.
The list of deaths identified from the first phase
mortality review will be compared with the list originally
reported in the RECORD trial results. If the first phase,
mortality review has not identified all of the deaths
originally reported in the RECORD trial results, additional
screening may be necessary.
Upon completion of first-phase mortality screening and
adjudication, DCRI will receive electronic data containing
treatment group assignment information (randomized and
actual treatment administered) from GSK and perform
statistical analysis of the mortality results.
Appendix Table V describes the objectives of the first
phase review.
Appendix Table V. RECORD study independent readjudication
objectives for the first phase: mortality
1. First phase: mortality
a. Without knowledge of assigned treatment arm or actual treatment
administered, review data from RECORD and identify all recorded
deaths
b. Identify causes and dates of deaths
c. Derive date of last survival follow-up for each patient.
d. Summarize source of death date⁎
e. Summarize rate and time to all-cause mortality in each of the 4
treatment groups; compare rosiglitazone (RSG) with control arms†
f. Summarize rate and time to CV death in each of the 4 treatment groups;
compare RSG with control arms†
2. Final analysis: compare trial results based on DCRI independent
readjudication with results from the original RECORD trial. Note that in
this report, the comparison will be done at the summary level only and
will involve neither patient-by-patient comparison nor integration of data
from the original and current adjudication efforts.
⁎ In case death dates are obtained from sources other than the CRF, such as
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All analyses will be performed on the 4447 patients
included in the intent-to-treat (ITT) population in the
original RECORD report.
Restrictionof the analysis to a prespecified “per protocol”
population (as a subset of the overall ITT population) is not
intended. However, as described in Section 6, follow-up for
time-to-event and event rate analyses may be limited to
independent third-party search.
† The primary analysis compares the RSG and SU/MET groups combined across
background therapy strata.Appendix Figure 1. Timing of first and second phases. Thisspecific study phases defined to reduce the potential for
bias in treatment effect estimation.
5. End points
The following end points will be summarized with time-
to-event and event rate per 100 patient-year analyses. Note
that this SAP describes the analysis of first phase only.
First phase (mortality)
1. All-cause mortality
2. CV mortality
3. Non-CV mortality
Adjudication of deaths as CV, non-CV, or unknown
causewill be donewith 2 differentmethods, one using the
original RECORD CEC definitions and one using contem-
porary definitions under development by FDA through
the Standardized Data Collection for Cardiovascular Trials
Initiative. Analyses of CV and non-CV mortality will be
done for each method of adjudication.
End point status and end point dates for analyses of
these end points will come from the DCRI CEC database
containing the results of readjudication of identified
cases. Last contact dates for vital status will be derived
from the following sources:
1. RECORD database previously submitted by GSK to the
FDA
2. Additional CRF data or documentation supplied to the
DCRI by GSKSAP describes analyses for the first phase (mortality) only.
Appendix Table VI. Determination of survival status fromVITALS
CRF module
roup Description
Complete survival status based on reported death date or vital
sign assessment after August 24, 2008
Incomplete survival status—patients not included in group I
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party independent search, if conducted
4. Individual data received from any DCRI site queries
conducted
6. Study phases and derivation of follow-up dates
6.1. Definition of study phases for mortality
analysis. The initial DCRI SAP provided a general
description (Appendix I, Protocol AVD115170, Version
1.0, Section 6) of plans for derivation of randomized
treatment phase (RTP), CV follow-up (CVFU), and survival
status follow-up (SSFU). The CVFU phase for a study
subject involved regular examinations and telephone
contacts to identify CV hospitalizations and key safety and
efficacy outcomes, in addition to deaths. Study subjects
who wished to leave the CVFU phase had the option to
participate in the SSFU phase, which would require less
frequent contact and would only assess vital status.
For this report, the follow-up period for the mortality
analysis is based on all available follow-up where vital
status could be reliably assessed and does not depend on
whether follow-up occurred more frequently, as in the
CVFU, or less frequently, as in the SSFU. For this reason,
end of CVFU and end of SSFU phases will not be derived
for the mortality analysis.
Derivation of the RTP is described in Section 6.3.
6.2. End of survival follow-up
6.2.1. Determination of death dates.Death dates will be identified
by DCRI CEC as part of the adjudication process. When
there is insufficient information to allow determination of
the date of death, imputation will be done as described in
Section 6.2.2
6.2.2. Imputation of dates. In general, incomplete survival follow-
up and death dates will be imputed to the earliest date
consistent with the recorded information. For example, if
the only the month and year are reported, the imputed date
will be the first of themonth. If only the year is reported, the
imputed date will be the first of the year. In cases where the
year is not recorded, no algorithm is planned, and any
imputation will be done on a case-by-case basis, taking into
account other available dated information for that patient.
If, by using the above algorithm, an imputed death date
precedes the date last known alive, the date of death in
the analysis will be the date last known alive + 1 day.
6.2.3. Parsimonious approach to end of survival follow-up. The
parsimonious approach to derivation of last follow-up dates
for survival will require documented face-to-face contact at
study visits where 1 or more of the following parameters
were recorded on the VITALS module of the CRF:
• Blood pressure (systolic or diastolic)
• Height
• Weight
• Waist circumference
• Hip circumference
The date of last follow-up for patients without a
reported death will be the latest visit date where any ofthe above vital signs have been recorded. Patients who
are reported to have died or who have values for any of
the above parameters recorded on the VITALS panel after
August 24, 2008, will be considered to have completed
survival follow-up (group I, Appendix Table VI).G
I
IIBased on preliminary review of RECORD electronic
databases, approximately 85% of patients are in group I.
Sections 6.2.4 to 6.2.6 describe approaches to obtaining
additional vital status information and deriving additional
follow-up from the existing RECORD data for the patients
remaining in group II.
6.2.4. Survival follow-up for primary analysis. Additional follow-up
information for patients in group II (Appendix Table VI)will
be used in the primary analysis of all-cause, CV, and non-CV
mortality. There are 3 sources for the additional follow-up
information: RECORD electronic database, independent
third-party search, and DCRI internal review of CRFs and
associated documentation.Use of these sources is described
in Sections 6.2.4.1 to 6.2.4.3, respectively.
The date of last follow-up (for the primary analysis) for
patients not reported to have died will be the latest of the
dates described in Section 6.2.4.1 to 6.2.4.3. For patients
who have died, the DCRI CEC will review available
information to identify dates of death. In cases where the
date of death cannot be determined imputation will be
done as described in Section 6.2.2. All deaths occurring
on or before December 31, 2008, will be included in the
primary analysis.
6.2.4.1. Vital signs recorded in 2008 with last contact
after August 24, 2008, by telephone visit. Patients in
group II (Appendix Table VI) who had a face-to-face study
visit with vital signs recorded at any time during 2008 and
a telephone visit after August 24, 2008, will be considered
to have complete follow-up for survival. The date of last
follow-up will be date of the latest telephone visit on or
before December 31, 2008.
6.2.4.2. Independent third-party search. DCRI
may contract an independent third party to conduct a
search for dates of follow-up or death for patients in
group II (Appendix Table VI) who have limited or
conflicting follow-up information available in the RE-
CORD data. For patients shown to be alive later than the
last face-to-face study visit and not reported to have died,
the last observation date will be determined by the
information from the third-party search. The date of last
follow-up will be the latest date known alive on or before
December 31, 2008. For patients known to be dead based
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be determined as described in Section 6.2.1.
6.2.4.3. DCRI internal review of CRFs and additional
documentation. Dates of follow-up or death may be
obtained by DCRI review of CRFs or additional studyNote: Primary analysis end of observation date is described in Boxes A, C, E,
to-face visit where vitals were collected.documentation. This source includes, but is not limited
to, results of an effort by GSK to confirm survival status on
437 patients withdrawn from CV follow-up and for whom
survival status at study end was not obtained from a clinic
visit. This effort was conducted from November 2010 toand F. For patients entering Box F, the last date alive is the latest face-
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documented by insertion of relevant information in
individual patient CRF packets. For patients shown to
be alive later than the last face-to-face study visit and not
reported to have died, the last observation date will be
determined by the information from DCRI CRF review.
The date of last follow-up will be the latest date known
alive on or before December 31, 2008. For patients
shown to be dead, the death date will be determined as
described in Section 6.2.1.
6.2.5. Derivation of survival dates from test dates and reported patient
events. The electronic database for patients with incom-
plete survival follow-up for the primary analysis will be
screened for dates of specific patient visits or events
which are later than last follow-up dates derived in
Section 6.2.4. (Incomplete survival follow-up means a
patient is not reported to have died, and the date last
observed alive is before August 24, 2008). The modules to
be screened contain dates of electrocardiogram assess-
ments, laboratory tests, microvascular (diabetes-related)
end points, AEs, and fractures. In this approach to
survival follow-up, the date last observed alive is defined
as the later of
• the latest onset or event date found in these modules
and
• the date last observed alive derived using the
method outlined in Section 6.2.4.
Analyses using follow-up derived from dates of
electrocardiogram assessments, laboratory tests, micro-
vascular (diabetes-related) end points, AEs, and fractures
will not be considered primary and will be done only to
assess the impact of incomplete follow-up documented
from other sources.
6.2.6. Survival status follow-up and third-party searches within the
RECORD study. For patients whose vital status after August
24, 2008, cannot be determined by the method described
in Sections 6.2.3 to 6.2.5, an additional method of
deriving follow-up dates for mortality analysis will use
dates obtained from survival status follow-up and third-
party searches conducted as part of the RECORD study
and included in the electronic database. With this
method, the date last observed alive will be defined as
the later of
• the date last observed alive basedon telephone contact
with the patient, health care worker, or friend/
relative/neighbor/other person or through third-party
sources reported in the RECORD CRFs and
• the date last observed alive derived using themethod
outlined in Section 6.2.4.
If application of this method increases observed study
follow-up by at least 130 patient-years, then a sensitivity
analysis for all-cause and CV mortality will be done. (130
patient-years is the approximate incremental amount offollow-up that would result in a reduction in estimated
event rate of at least 0.0001, assuming 300 events and an
initial value of 20,000 patient-years of follow-up.)
6.2.7. Flowchart describing derivations of end of survival follow-up.
6.3. Derivation of end dates for randomized
treatment phase. The RTP is defined as the period of
treatment with randomized add-on study medication
(RSG, SU, or MET) and will include all visits from baseline
until the earlier of study end or premature discontinuation
from randomized study medication. For patients random-
ized to RSG, the end of RTP will be the date of last
recorded dose of RSG. For patients randomized to SU/
MET, the end of RTP will depend on the background
therapy stratum. End of RTP for patients in the back-
ground SU group will be defined as the date of the last
recorded dose of MET. End of RTP for patients in the
background MET group will be defined as the date of the
last recorded dose of SU.
Last date of add-on studymedicationmay bederived from
2 different sources on the CRF. One source is the “ADD-ON
STUDY MEDICATION RECORD,”which records dosing of
each oral therapy administered in the intervals between
visits. A second source is the reported “Date of final dose of
add-on study medication,” which may appear in 1 of 2
places on the CRF. These are as follows:
• “Date of final dose of add-on study medication”
before leaving the randomized treatment phase
from the STUDY CONTINUATION/WITHDRAWAL
module or
• “Date of final dose of add-on study medication” from
the STUDY COMPLETION module.
The “ADD-ON STUDY MEDICATION RECORD” will
serve as the primary source for deriving end of RTP. In
cases where, due to missing or incomplete data, end of
RTP cannot be derived from this part of the CRF, “Date of
final dose of add-on study medication” will be used as the
end of RTP. For patients in the ITT population who have
no record of having received study drug, the end of RTP
will be set to 1 day after randomization.
The end of RTP for patients who died while still
receiving randomized treatment will be the CEC adjudi-
cated date of death.
7. Analysis methods
7.1. Comparison of reported RECORD trial results
and DCRI independent readjudication. Comparisons
of the results from original RECORD trial results and the
DCRI independent readjudication results will be done only
at the summary level. Integration of the original data and
the DCRI-readjudicated data for estimation of treatment
effect (RSG vs control arm) is not planned for this report.
7.2. Planned analyses of end points. The objectives
of the statistical analyses will be the comparison of the
RSG and MET/SU treatment groups and estimation of the
216.e22 Lopes et al
American Heart Journal
August 2013treatment effect for the end points listed in Section 5.
Reference date for time to event analysis will be date of
randomization, with the exception of landmark analyses
described in Section 7.3.4. For the end point of
cardiovascular mortality, the primary analyses will classify
deaths of unknown cause as cardiovascular.
For time-to-event analyses, the estimated treatment
effect will be expressed in terms of the observed HR θobs
(= λr,obs/λc,obs) and 2-sided 95% confidence limits, where
λr and λc are the respective hazards for the RSG and MET/
SU combination groups.
The estimate of θ for each end point will be made using
a Cox proportional hazard (PH) model, stratified by
background treatment (MET or SU). The HR and 95% CI
and 2-sided P values for the test of a difference from the
null HR of 1 will be calculated. A test for interaction
between treatment group and stratum will assess the
homogeneity of the treatment effect across strata. The
test for interaction may be considered significant if P ≤
.10. Secondary analyses will be done estimating θ with a
Cox PH model, and 95% confidence limits, in each of the
strata, MET or SU background treatment. If there is
evidence of significant treatment group by stratum
interaction (P ≤ .10), the within-stratum estimates of θ
may be the most relevant.
Because the DCRI independent readjudication is
retrospective in nature and was not planned as part of
the RECORD trial, and also involves multiple end points,
study phases, and methods for deriving censoring dates,
formal testing for noninferiority lacks usual controls over
type I and type II error.
Unadjusted Kaplan-Meier survival curves, HRs and 95%
confidence limits, and incidence rates per 100 person-
years are planned for all-cause mortality, CV mortality,
and non-CV mortality using the survival primary analysis
follow-up derivation described in Section 6.2.4.
This SAP describes a number of time-to-event analyses,
which are considered exploratory, including sensitivity
analyses and subgroup analyses. These analyses will be
summarized with HRs (RSG/control) and 95% confidence
limits and unadjusted Kaplan-Meier survival curves. A
table will be presented showing median and mean follow-
up time for each end of follow-up derivation method by
treatment arm (RSG vs MET/SU) overall and by stratum.
When analyses of CV or non-CV mortality are done,
results will be presented separately for the 2 methods
used in adjudication of cause of death (original RECORD
CEC definition and contemporary definitions under
development by FDA through the Standardized Data
Collection for Cardiovascular Trials Initiative.)
7.3. Additional elements of the report
7.3.1. Summaries of adjudication. Descriptive statistics will
summarize the results of the selection of potential end
points and the adjudication results, as shown in the
following bullets. Summaries will be produced by
treatment arm and for the total population.• Number of patients triggered for adjudication
• Data sources triggering cases selected for
adjudication
• Number (%) of deaths classified by cause (CV death,
non-CV, cause unknown) and sufficiency of infor-
mation (sufficient, insufficient), as defined by the
original RECORD CEC and also by contemporary
definitions under development by FDA through the
Standardized Data Collection for Cardiovascular
Trials Initiative.
7.3.2. On-treatment analyses. Two on-treatment analyses of all-
cause and CV mortality will be done, censoring patients
alive on the last day of randomized treatment + 30 days,
and the last day + 60 days. These analyses will be done
using the survival primary analysis follow-up derivation
described in Section 6.2.4, with cause of death adjudi-
cated by the original RECORD CEC definitions and also
contemporary definitions under development by FDA
through the Standardized Data Collection for Cardiovas-
cular Trials Initiative.
7.3.3. Subgroup analyses. Estimates of HRs (RSG/control) and
95% confidence limits will be computed for all-cause
mortality and CV mortality for the following subgroups.
No imputation will be done for subgroup variables with
missing values on the electronic data sets.
• Demography
◦ Sex (male, female)
◦ Age in years (b60, ≥60)
• Baseline risk factors
◦ Duration of diabetes in years (b6.0, ≥6.0)
◦ Body mass index in kg/m2 (b30.0, ≥30.0)
◦ Previous ischemic heart disease (yes, no)
• Baseline CV drug use
◦ Angiotensin-converting enzyme inhibitors (yes,
no)
◦ Statins (yes, no)
◦ Nitrates (yes, no)
• By country
7.3.4. Sensitivity analyses. The following sensitivity analyses
will be done to determine if the results from the DCRI
independent readjudication of the RECORD trial are
robust.
To assess the impact of classifying deaths of unknown
cause as cardiovascular, analyses of CV mortality will be
repeated, classifying deaths of unknown cause as
noncardiovascular (original CEC and contemporary
definitions under development by FDA through the
Standardized Data Collection for Cardiovascular Trials
Initiative.) This analysis will use the primary method of
survival follow-up as defined in Section 6.2.4.
To assess the impact of censoring date derivation, time-
to-event and event rate analyses for overall mortality and
cardiovascular mortality (contemporary definitions under
development by FDA through the Standardized Data
Collection for Cardiovascular Trials Initiative only) under
the different sets of rules for deriving study phase end
║ Note that, according to protocol, patients in the RSG-containing
arms could add a third drug (SU for patients receiving MET + RSG or
MET for patients receiving SU + RSG) in case of loss of glycemic
control with the dual-drug treatment and could remain on treatment.
Patients in the control arm (MET + SU), however, did not have the
option of the addition of a third drug, in case of loss of glycemic
control with dual-drug treatment, and would be withdrawn from
randomized treatment. By design, the RTP would tend to be longer
in the RSG-containing arm than in the control arm.
Lopes et al 216.e23
American Heart Journal
Volume 166, Number 2dates described in Sections 6.2.3, 6.2.5, and 6.2.6 (if
follow-up is increased by at least 130 patient-years
compared with the method used in Section 6.2.5) will
be compared.
To assess a possible impact of Amendment 7, time-to-
event and event rate analyses for overall and cardiovas-
cular mortality (contemporary definitions under develop-
ment by FDA through the Standardized Data Collection
for Cardiovascular Trials Initiative only, primary method
of survival status date derivation only, as in Section 6.2.4)
will be compared.
• censoring all patients alive on February 27, 2006, the
date of Amendment 7
• with a landmark analysis, assuming follow-up starts
on February 27, 2006, and including all patients alive
on that date
To assess the possible impact of a published interim
report23 of the RECORD trial, time-to-event and event rate
analyses for overall and cardiovascular mortality (con-
temporary definitions under development by FDA
through the Standardized Data Collection for Cardiovas-
cular Trials Initiative only, primary method of survival
status date derivation only, as in Section 6.2.4), will be
compared.
• censoring all patients alive on June 5, 2007, the date
of the interim report
• with a landmark analysis, assuming follow-up starts
on June 5, 2007, and including all patients alive on
that date
To assess the possibility of informative censoring, a Cox
PH analysis of time-to-censoring will be done, where
patients are counted as having events on the dates of
censoring, whereas events are treated as “censored
without event” for overall mortality and cardiovascular
mortality (contemporary definitions under development
by FDA through the Standardized Data Collection for
Cardiovascular Trials Initiative only, primary method of
survival status date derivation only, as in Section 6.2.4). A
differential risk of censoring between RSG and control
arms would indicate the possibility of informative
censoring.
To assess the impact of selection of study cutoff date,
analyses of all-cause and CV mortality will be done using
August 24, 2008, as the cutoff (instead of December 31,
2008). This analysis will be done for cause of death
adjudicated by contemporary definitions under develop-
ment by FDA through the Standardized Data Collection for
Cardiovascular Trials Initiative only, using the primary
method of survival status date derivation, as in Section 6.2.4.
Appendix A: Study Phases as Defined in RECORD
Reporting and Analysis Plan
From (Appendix I, Protocol AVD115170, Version 1.0,
Section 6)The DCRI independent review of data from the RECORD
trial will include derivation of follow-up dates for each of the
3 study phases, defined in the RECORD Reporting and
Analysis Plan (Curtis PS, Crisp A, 2009, unpublished).
• Randomized treatment phase (RTP)
• CV follow-up (CVFU)
• Survival status follow-up (SSFU).
For each patient, the last date of RTP should be no later
than the last date of CVFU, which should be no later than
the last date of SSFU. The following description of study
phases is copied from Section 8.5 of the RECORD
Reporting and Analysis Plan.
“For the management of patient disposition and
withdrawals, the following definitions will be used for
tracking the various mechanisms available for follow-up:
• CV follow-up phase is the entire period of follow-up
for CV events and comprises the following elements:
• Randomized treatment phase║ is the period of
treatment with add-on study medication (RSG, SU,
or MET) and will include all visits from baseline
until study end, or premature discontinuation
from study medication, whichever is sooner.
• Post-randomised treatment CV follow-up phase is
the period of follow-up from the time of
premature discontinuation of study medication
until study end, complete withdrawal, or move to
survival status updates only, whichever is sooner.
This phase comprises:
• CV outcomes phase (post-randomised treat-
ment phase);
• Tracking substudy: post-randomised treatment
follow-up for subjects withdrawn before Proto-
col Amendment 7.
• Survival status follow-up is follow-up of survival
status for subjects after withdrawal from CV follow-
up phase.”
As noted above, the RTP may be longer in the RSG arm
than in the control arm. For the purpose of identifying
study phases of comparable length in the 2 treatment
arms, DCRI may also consider a randomized dual-
treatment phase (RDTP), provided that the RECORD
database contains sufficient information to derive end of
dual treatment for most patients in the trial.
End point Event date Censoring date
All-cause
mortality
Date of death as
determined by the
DCRI CEC adjudication
The latest of the
following dates:
• Date of the last visit
with documented vital
signs data
• Date of the patient's
DCRI CEC adjudicated
nonfatal CV event
CV mortality Date of death for
deaths classified
as cardiovascular.
For patients who died
of non-CV cause and
did not withdraw from
CV follow-up, the
DCRI CEC adjudicated
date of death.
For patients who did
not die, the latest of the
following dates:
• Date of the last visit
with documented
vital signs data
• Date of the patient's
DCRI CEC adjudicated
nonfatal CV event
• Date the patient
withdrew from
follow-up
Abbreviation Definition
CEC Clinical events classification
Cox PH Cox proportional hazard (model)
CV Cardiovascular
CVFU Cardiovascular follow-up
DCRI Duke Clinical Research Institute
FDA US Food and Drug Administration
GSK GlaxoSmithKline
MACE Major adverse cardiac end points
MET Metformin
MI Myocardial infarction
RECORD Rosiglitazone Evaluated for Cardiac
Outcomes and Regulation of glycaemia
in Diabetes
RSG Rosiglitazone
SAP Statistical analysis plan
SU Sulphonylurea
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phases may depend on patient experiences postrando-
mization, other phases may also be defined with the
intent of making the length of the phases independent of
postrandomization experience. Rules for derivation of
additional phases will be documented in an addendum to
the SAP, signed before code break.
Determination of the end of study phase dates is
complicated by a number of factors including
• the overall complexity of the RECORD trial
• the length of planned follow-up and usual reasons
for loss to follow-up
• treatment discontinuations resulting from loss of
glycemic control
• unscheduled visits at physician discretion to ensure
regulation of glycemic control
• lengthening of the RTP and CVFU following
Amendment 7 (February 27, 2006) to achieve
median follow-up of 6 years
• multiple sources on the CRF from which to derive
end of study phase dates, and
• as typical in trials with long follow-up, uncertainty of
visit and contact dates resulting in incomplete date
fields on the CRF.
Owing to these factors, precise determination of end of
study phase dates cannot be done for all patients, and in
some cases, algorithms are required to provide approx-
imations of the length of study phases. Approximation of
the length of study phases for some patients may result in
error in estimates of event rates or time-to-event analyses,
and because RECORDwas an open-label trial, there is also
a potential for bias in treatment comparisons.
In its independent evaluation, DCRI intends to use at least 2
methods for deriving end of study phase dates. The first
methodwill use a parsimonious approach, attempting to find
as simple an algorithmaspossible todefine studyphases.With
the second method, DCRI will develop a more complex
algorithm, taking into account the data patterns for specific
patients for whom the parsimonious approach may give
clearly inaccurate or conflicting results. If deemed necessary,
additional approaches may also be considered. The parsimo-
nious approach, due to its simplicity, may have less potential
for bias at the expense of reduced precision in study phase
definition for somepatients. During derivation of end of study
phase dates, DCRI will be blinded to treatment assignment
and treatment actually administered. Details of the methods
used in deriving end of study phase dates will be included in
an addendum to this SAP, signed before code break.
For determination of follow-up dates for analysis of
mortality, we will initially consider a parsimonious
approach such as the one described below. It is
anticipated that this initial approach will not identify
valid follow-up dates for all patients, and we expect to
make appropriate modifications in an attempt to deter-
mine accurate dates for the entire study population:Appendix F. Statistical analysis plan,
DCRI independent review, and readjudi-
cation of the RECORD trial, second phase
(major adverse cardiac end points)
Prepared by
Gail Hafley (Senior Statistician, DCRI)
Robert Bigelow (Associate Director of Statistics, DCRI)
January 24, 2012
Duke Clinical Research Institute1. Abbreviations
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This analysis plan describes the second phase of the
RECORD readjudication/reanalysis, focusing on the major
adverse cardiac end points (MACE) and the components
cardiovascular death, MI, and stroke. This document
supplements the first-phase SAP, dated July 13, 2011,
which described the methods used in the analysis of
mortality. General information about the RECORD study
can be found in the SAP dated July 13, 2011.
3. Objectives and operational overview
In the Re-adjudication Protocol AVD115170 for the
Rosiglitazone Evaluated for Cardiovascular Outcomes and
Regulation of glycaemia in Diabetes trial (RECORD)
Report of the First Phase: Blinded readjudication of All-
cause Mortality and Cardiovascular Mortality Final De-
cember 13, 2011, DCRI attempted to determine vital
status at the end of the study for as many patients as
possible, screened the data for all suspected deaths, and,
for those patients determined to have died, classified the
deaths according to cause (cardiovascular [CV], non-CV,
or unknown). Time-to-event analyses were done for all-
cause, CV, and non-CV mortality, comparing event rates
in the RSG and MET/SU arms.
In the second phase, CEC will use predefined criteria to
review all suspected incidences of nonfatal MI or nonfatal
stroke and judge whether an MI or stroke has actually
occurred. For patients deemed to have had an MI or
stroke, the CEC will identify the date of the event. DCRI
will use 1 or more algorithms to determine the last known
event-free date in patients deemed not to have experi-
enced an MI or stroke. All persons involved in data review
and adjudication will be blinded to randomized treatment
arm and actual treatment administered.
Upon completion of first-phase mortality screening and
adjudication, DCRI received electronic data containing
treatment group assignment information (randomized
and actual treatment administered) from GSK and
performed statistical analysis of the mortality results. AAppendix Table VII. RECORD study independent readjudication obje
1. Second phase: MACE
a. Without knowledge of assigned treatment arm or actual treatment administe
stroke
b. Adjudicate events identified in item a using same definitions as in RECORD p
c. Adjudicate events identified in item a using the FDA standardized definitions
d. Derive date of last follow-up without event for patients who did not have CV
e. Summarize MI and stroke (with definitions used in the original RECORD CE
compare rosiglitazone (RSG) with control arms
f. Summarize the combination end point of CV death, MI, or stroke (with definit
each of the 4 treatment groups; compare RSG with control arms
2. Final analysis: compare trial results based on DCRI independent readjudicatio
comparison will be done at the summary level only and will involve neither pa
current adjudication efforts.†
⁎ The DCRI readjudication of events used the event definitions from the original RECORD s
adjudicators' clinical judgment, without consideration for rules that may have been used by t
†Analyses of the original RECORD trial data will not be performed. However, a descriptive di
DCRI independent readjudication will be included in the final study report.lead statistician, a faculty/review statistician, a faculty
cardiologist, and an editor from DCRI were unblinded to
treatment group assignment and prepared the statistical
analysis and study report of first-phase mortality data. The
statistical analysis of second phase data will be done by
separate lead and faculty/review statisticians who, during
screening and adjudication of the data, have remained
blinded to treatment group assignment and the results
from analysis of mortality.
Appendix Table VII describes the objectives of the
second phase review.
4. Populations
All analyses will be performed on the 4447 patients
included in the intent-to-treat (ITT) population in the
original RECORD report.
Restriction of the analysis to a prespecified “per
protocol” population (as a subset of the overall ITT
population) is not planned.
5. End points
5.1. Primary end points. The following end points
will be summarized with time-to-event and event rate per
100 patient-year analyses. Time-to-event and event rate
analyses for MI and stroke take into account only the first
occurrences of these events.
Second phase (MACE)
1. First occurrence of cardiovascular (or unknown cause)
mortality, nonfatal MI, or nonfatal stroke, MACE
2. MI (fatal or nonfatal)
3. Nonfatal MI
4. Stroke (fatal or nonfatal)
5. Nonfatal stroke
An MI will be classified as fatal only if it is included as a
cause of death on the adjudication form. The date of the
fatal MI will be the date of the most recent occurrence of
an adjudicated MI within 30 days of the date of death. If
there is no adjudicated MI within 30 days of the date ofctives for the second phase: MACE
red, review data from RECORD and identify patients with suspected MI or
rotocol; possibly new rules for event dates⁎
for cardiovascular trials
death, MI, or stroke
C effort and the readjudication effort) in each of the 4 treatment groups;
ions used in original RECORD CEC effort and the readjudication effort) in
n with results from the original RECORD trial. Note that in this report, the
tient-by-patient comparison nor integration of data from the original and
tudy CEC. However, event dates were determined by the DCRI CEC based on the
he original RECORD study CEC.
scussion of previously published results from the RECORD trial and the results from the
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Classification of fatal stroke will be done similarly.
The MACE composite end point (number 1 in the above
list) will include any additional data on CV death obtained
after the database lock for the first-phase mortality report,
including identification of previously unknown deaths,
new information on patient follow-up, or updated
classifications of cause of death.
An updated analysis of all-cause and CV mortality may
be performed if additional deaths are found that occurred
on or before December 31, 2008, or information has been
obtained that results in a change of event classification
(eg, CV death/no CV death), or a substantial amount of
additional follow-up has been obtained. In particular,
events adjudicated as nonfatal MIs or nonfatal strokes for
patients not reported to have died may extend the
survival follow-up periods for those patients, if the events
occurred after the date last reported alive in the primary
analysis in the first phase report. If performed, the
updated analysis of all-cause and CV mortality will use
the primary method of survival defined in Section 6.2.4 of
the phase I SAP, dated July 13, 2011, incorporating the
additional information found.
Adjudication of the events (nonfatal MI, fatal MI,
nonfatal stroke, fatal stroke, and death from CV or
unknown cause) will be done with 2 different methods,
one using the original RECORD CEC definitions and one
using contemporary definitions under development by
FDA through the Standardized Data Collection for
Cardiovascular Trials Initiative. Separate analyses will be
reported for each adjudication method.
5.2. Additional composite end points. The follow-
ing composite end points will be summarized with time-
to-event and event rate per 100 patient-year analyses.
Time-to-event and event rate analyses will be based on the
first occurrence of any of the events in the composite.
1. First occurrence of all-cause mortality, nonfatal MI, or
nonfatal stroke
2. First occurrence of cardiovascular (or unknown cause)
mortality or nonfatal MI
3. First occurrence of all-cause mortality or nonfatal MI
6. Derivation of follow-up dates
In the RECORD trial, not all patients were followed up
uniformly to the end of the study (final visits to be done
August 24, 2008, through December 24, 2008). The DCRI
analysis considered patients whose end point status was
known as of August 24, 2008, to have completed follow-
up. All events occurring through December 31, 2008,
were included in the primary analysis.
Derivation of the follow-up period for nonfatal MI and
nonfatal stroke will be done similarly to the derivation of
the parsimonious approach to survival follow-up, de-
scribed in Section 6.2.3, of the first-phase SAP (July 13,2011). If a patient is determined to have at least 1 nonfatal
MI, the last follow-up date for this end point is the date of
the first occurrence of the nonfatal MI, and follow-up is
considered uncensored. If a patient does not have a
nonfatal MI, the last follow-up date for this end point is
censored at the date of the last visit at which vital signs
were recorded. A similar approach is used to derive
follow-up dates for nonfatal stroke. Follow-up dates for
nonfatal MI and nonfatal stroke are derived independent-
ly. For example, if a patient is determined to have a
nonfatal MI, the date of the nonfatal MI will not be used to
derive end of follow-up for nonfatal stroke.
For patients reaching the end point of MI (fatal or
nonfatal), the last follow-up date is the date of the earliest
event, and follow-up is uncensored. Patients without an
MI are considered to have censored follow-up at the date
of the last visit at which vital signs were recorded. A
similar approach is used to derive follow-up dates for
stroke (fatal or nonfatal). Follow-up dates for MI and
stroke are derived independently.
Last follow-up date for patients experiencing at least 1
of the MACE events will be the date of the first
occurrence of any of those events. Last follow-up date
for patients who did not experience any MACE event will
be the date of the last study visit at which vital signs were
recorded.
Because some patients did not have regularly scheduled
visits with vital sign recording through the end of the
study, the follow-up period may be dependent on the
occurrence of an event. As a result, follow-up periods
may differ from one event to another for the same
patient.
7. Analysis methods
7.1. Comparison of reported RECORD trial results
and DCRI independent readjudication. Comparisons
of the results from the original RECORD trial and the
DCRI independent readjudication will be done only at
the summary level. Integration of the original data and the
DCRI-readjudicated data for estimation of treatment
effect (RSG vs control arm) is not planned for this report.
Planning for this analysis, which involves interactions
with DCRI, FDA, GSK, the RECORD Steering Committee,
and the original RECORD CEC, is unlikely to be
completed in time for inclusion into this report. See the
DCRI Re-adjudication Protocol AVD115170 (January 28,
2011) Section 5.1, last bullet point. Additional analyses
comparing patient level adjudication results from the
original RECORD trial to the results of the DCRI
independent readjudication may be performed at a later
date and described separately.
7.2. Planned analyses of end points. The objectives
of the statistical analyses will be the comparison of the
RSG and MET/SU treatment groups and estimation of the
treatment effect for the end points listed in Section 5.
Reference date for time-to-event analysis will be date of
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described in Section 7.3.3. For end points of CV mortality
or MACE, the primary analyses will classify deaths of
unknown cause as CV.
Because the DCRI independent readjudication is
retrospective in nature and was not planned as part of
the RECORD trial, and also involves multiple end points,
study phases, and methods for deriving censoring dates,
formal testing for noninferiority lacks usual controls over
type I and type II error. Estimation of the comparative
cardiovascular event risk between patients receiving RSG
and those receiving SU/MET is the major objective of the
readjudication effort, and observed differences and
confidence limits will be emphasized over nominal
statistical significance inferred from P values.
Analyses described in Sections 7.2.1 and 7.2.2 will be
presented separately for the 2 methods used in adjudica-
tion of MI, stroke, or cause of death (original RECORD
CEC definition and contemporary definitions under
development by FDA through the Standardized Data
Collection for Cardiovascular Trials Initiative.)
Observed treatment differences in any of the individual
components of MACE should be interpreted with caution
because of the possibility of competing risks related to
treatment. For example, an increase of nonfatal strokes in
one treatment arm may not indicate increased risk with
that arm, if more fatal strokes occurred in the other arm.
7.2.1. Primary analyses. Person-years of follow-up will be
displayed for each of the end points in Section 5, by
randomized treatment arm and background therapy.
Person-years of follow-up will be the sum of years from
randomization to event or censoring. A table will be
presented showing median and mean follow-up time for
each end point described in Section 5.1 by treatment arm
(RSG vs MET/SU) overall and by stratum.
For time-to-event analyses, the estimated treatment
effect will be expressed in terms of the observed HR jobs
(= lr,obs/lc,obs) and 2-sided 95% confidence limits, where lr
and lc are the respective hazards for the RSG and MET/SU
combination groups.
The estimate of j for each end point will be made using
a Cox proportional hazard (PH) model, stratified by
background treatment (MET or SU). The HR and 95% CI
and 2-sided P values for the test of a difference from the
null HR of 1 will be calculated. A test for interaction
between treatment group and stratum will assess the
homogeneity of the treatment effect across strata. The
test for interaction may be considered significant if P ≤
.10. Secondary analyses will be done estimating j with a
Cox PH model, and 95% confidence limits, in each of the
strata, MET or SU background treatment. If there is
evidence of significant treatment group by stratum
interaction (P ≤ .10), the within-stratum estimates of j
may be the most relevant.
Unadjusted Kaplan-Meier survival curves, HRs and 95%
confidence limits, and incidence rates per 100 person-years are planned for MI, nonfatal MI, stroke, nonfatal
stroke, and MACE using the follow-up derivation de-
scribed in Section 6. Updated analyses of all-cause
mortality and CV (including unknown cause) mortality
may be done if additional death or follow-up information
has become available since the completion of the first-
phase mortality report (December 13, 2011.)
7.2.2. Summaries of adjudication. Descriptive statistics will
summarize the results of the selection of potential end
points and the adjudication results, as shown in the
following bullets. Summaries will be produced by
treatment arm and for the total population.
• Number of patients triggered for adjudication
• Data sources triggering cases selected for
adjudication
• Number (%) of events classified by sufficiency of
information (sufficient, insufficient), as defined by
the original RECORD CEC and also by contemporary
definitions under development by FDA through the
Standardized Data Collection for Cardiovascular
Trials Initiative
7.3. Additional elements of the report. This section
describes time-to-event analyses, which are considered
exploratory, including sensitivity analyses and subgroup
analyses. These analyses will be summarized with HRs
(RSG/control) and 95% confidence limits and unadjusted
Kaplan-Meier survival curves.
The analyses described in Section 7.3 are planned for
events adjudicated by the New (Standardized Data
Collection for Cardiovascular Trials Initiative) method
only. If the primary analysis shows qualitatively different
results between the New definitions and the Original
definitions (used in the original RECORD trial) for an end
point, the analyses described below may also be
conducted with events adjudicated by the Original
definitions. A preliminary definition for “qualitatively
different” is a relative difference of 10% or greater in the
HRs obtained between the 2 methods of adjudication.
This definition is intended to be used as a guide and will
not necessarily be strictly applied. Other criteria, such as
clinical relevance of a particular result, may be used to
decide whether to produce analyses for events adjudi-
cated by the Original definitions.
Analyses described in Section 7.3 use follow-up
derivations described in Section 6.
7.3.1. On-treatment analyses. Two on-treatment analyses of the
end points described in Section 5.1 will be done,
censoring patients alive on the last day of randomized
treatment + 30 days, and the last day + 60 days.
7.3.2. Subgroup analyses. Estimates of HRs (RSG/control) and
95% confidence limits will be computed for MI (fatal or
nonfatal), Stroke (fatal or nonfatal), and MACE for the
subgroups defined below. No imputation will be done for
subgroup variables with missing values on the electronic
data sets.
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◦ Sex (male, female)
◦ Age in years (b60, ≥60)
• Baseline risk factors
◦ Duration of Diabetes in years (b6.0, ≥6.0)
◦ Body mass index in kg/m2 (b30.0, ≥30.0)
◦ Previous ischemic heart disease (yes, no)
◦ Baseline glycated hemoglobin (b7.4%, 7.4%-b7.8%,
7.8%-b8.4%, ≥8.4%)
• Baseline CV drug use
◦ Angiotensin-converting enzyme inhibitors (yes, no)
◦ Statins (yes, no)
◦ Nitrates (yes, no)
◦ β-Blockers (yes, no)
• By country
7.3.3. Sensitivity analyses. The following sensitivity analyseswill
be done to determine if the results from the DCRI
independent readjudication of theRECORD trial are robust.
To assess the impact of classifying deaths of unknown
cause as cardiovascular, analyses of MACE will be
repeated classifying deaths of unknown cause as non-CV.
To assess the impact of insufficient information available
for assessing whether or not an event occurred, analyses of
MI, stroke, and MACE will be repeated classifying events
with insufficient information as nonevents.
To assess possible impact of Amendment 7, time-to-
event and event rate analyses for MI, stroke, and MACE
will be compared:
• censoring all patients without event on February 27,
2006, the date of amendment 7
• with a landmark analysis, assuming follow-up starts
on February 27, 2006, and including all patients who
have not had an event before that date
To assess the possible impact of a published interim
report23 of the RECORD trial, time-to-event and event rate
analyses for MI, stroke, and MACE, will be compared:
• censoring all patients without event on June 5, 2007,
the date of the interim report
• with a landmark analysis, assuming follow-up starts
on June 7, 2007, and including all patients who have
not had an event before that date
To assess the possibility of informative censoring, a Cox
PH analysis of time-to-censoring, where patients are
counted as having events on the dates of censoring, will
be done, whereas events are treated as “censored without
event” for MI, stroke, and MACE. A differential risk of
censoring between RSG and control arms would indicate
the possibility of informative censoring.
To assess the impact of selection of study cutoff date,
time-to-event analyses of MI, stroke, and MACE will be
done using August 24, 2008 as the cutoff (instead of
December 31, 2008).
Other sensitivity analyses that will be considered
include the following:To examine the effect of a potential difference in follow-
up periods among the end points of MI, stroke, and CV
death, an analysis of MACE will be done taking into
account interval censoring. In this analysis, major
cardiovascular events determined by the occurrence of
a CV or unknown cause of death after the date of the last
face-to-face visit will be considered subject to interval
censoring, and the HR between RSG and control arms
will be estimated using the Weibull model, as described in
Lindsey and Ryan.24 In this analysis, the date of the MACE
event will not be the date of the CV or unknown cause
death; rather, it will be considered to occur between the
date of the last face-to-face visit and the date of death,
during a period when a nonfatal MI or stroke could have
occurred without being reported. This analysis will use
SAS PROC LIFEREG, and the model statement will be
expressed as “MODEL (LOWER, UPPER) = {treatment arm
indicator}/dist = weibull,” where
• For patients who do not have an MI, stroke, or CV or
unknown cause death
◦ LOWER = date of last face-to-face visit
◦ UPPER = missing
• For patients who have MACE determined by MI or
stroke
◦ LOWER = date of event
◦ UPPER = date of event
• For patients who have MACE determined by CV or
unknown cause death
◦ LOWER = date of last face-to-face visit
◦ UPPER = date of death
Because not all patients were followed up uniformly to
the end of the RECORD trial, estimates of the amount of
unobserved follow-up will be made, and the potential
impact on MACE will be assessed. Unobserved follow-up
will be calculated as the sum of time from the last visit at
which vital signs were recorded to August 24, 2008, for
patients who did not have MACE. (Note that patients who
were followed up to August 24, 2008, would be considered
to have completed the study follow-up.) Patients who had
MACE would be considered to have no unobserved follow-
up. We will simulate the occurrence of events between the
date last observed without event and December 31, 2008,
for patients who did not have MACE and were not followed
up to August 24, 2008. For each simulation run, the HR will
be estimated from a data set containing the observed and
simulated data. The distribution of the simulated outcomes
will be described. The simulations will be done for a variety
of assumed HRs, including the estimated HR from available
data as well as HRs adverse to RSG (25%, 50%, 75%, and
100% increased risk).
To obtain an estimate of the HR accounting for baseline
characteristics, a Cox PH model for the end points of MI,
stroke, and MACE will be generated adjusting for
variables described in Section 7.3.2 and possibly other
clinically relevant baseline factors.
